DocGo (DCGO) 10-K 27 Feb 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 25, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39618
Entity Registrant Name	DocGo Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2515483
Entity Address, Address Line One	685 Third Avenue
Entity Address, Address Line Two	9th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(844)
Local Phone Number	443-6246
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	DCGO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 286,324,968
Entity Common Stock, Shares Outstanding		101,982,549
Documents Incorporated by Reference	Portions of the Registrant’s Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Registrant expects to file such proxy statement with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2024.
Entity Central Index Key	0001822359
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	1013
Auditor Name	Urish Popeck & Co., LLC
Auditor Location	Pittsburgh, PA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 89,241,695	$ 59,286,147
Accounts receivable, net of allowance for credit loss of $5,873,942 and $6,276,454 as of December 31, 2024 and December 31, 2023, respectively	210,899,926	262,083,462
Prepaid expenses and other current assets	4,344,642	17,499,953
Total current assets	304,486,263	338,869,562
Property and equipment, net	14,881,411	16,835,484
Intangibles, net	25,728,813	37,682,928
Goodwill	47,432,550	47,539,929
Restricted cash	18,095,612	12,931,839
Operating lease right-of-use assets	11,958,698	9,580,535
Finance lease right-of-use assets	15,337,299	12,003,919
Investments	5,547,979	553,573
Deferred tax assets	8,422,034	11,888,539
Other assets	3,730,473	2,565,649
Total assets	455,621,132	490,451,957
Current liabilities:
Accounts payable	28,356,430	19,827,258
Accrued liabilities	49,896,796	91,340,609
Line of credit	30,000,000	25,000,000
Notes payable, current	12,515	28,131
Due to seller	28,656	7,823,009
Contingent consideration	4,973,152	19,792,982
Operating lease liability, current	3,844,561	2,773,020
Finance lease liability, current	4,694,467	3,534,073
Total current liabilities	121,806,577	170,119,082
Notes payable, non-current	5,215	41,586
Operating lease liability, non-current	8,599,072	7,223,941
Finance lease liability, non-current	10,031,138	7,896,392
Total liabilities	140,442,002	185,281,001
Commitments and contingencies
Stockholders’ equity:
Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 101,910,883 and 104,055,168 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively)	10,191	10,406
Additional paid-in-capital	321,087,583	320,693,866
Accumulated deficit	(1,402,167)	(21,394,310)
Accumulated other comprehensive income	1,221,869	1,484,905
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries	320,917,476	300,794,867
Noncontrolling interests	(5,738,346)	4,376,089
Total stockholders’ equity	315,179,130	305,170,956
Total liabilities and stockholders’ equity	$ 455,621,132	$ 490,451,957

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 5,873,942	$ 6,276,454
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	101,910,883	104,055,168
Common stock, shares outstanding (in shares)	101,910,883	104,055,168

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 616,555,132	$ 624,288,642	$ 440,515,746
Expenses:
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)	402,980,557	428,906,225	285,794,520
Operating expenses:
General and administrative	138,758,758	137,152,512	103,403,416
Depreciation and amortization	15,884,898	16,431,892	10,565,578
Legal and regulatory	17,146,891	13,082,569	8,780,590
Technology and development	11,589,402	10,858,724	5,384,853
Sales, advertising and marketing	1,505,900	2,801,740	4,755,161
Total expenses	587,866,406	609,233,662	418,684,118
Income (loss) from operations	28,688,726	15,054,980	21,831,628
Other (expense) income:
Interest (expense) income, net	(1,929,207)	1,684,399	762,685
Gain on remeasurement of warrant liabilities	0	0	1,127,388
Change in fair value of contingent liability	9,392,133	1,437,525	0
Finite-lived intangible asset impairment	(8,306,591)	0	0
Goodwill impairment	0	0	(2,921,958)
(Loss) gain on equity method investments	(316,044)	(343,336)	8,919
(Loss) gain on remeasurement of operating and finance leases	(32,363)	(866)	1,388,273
Gain on bargain purchase	0	0	1,593,612
Gain (loss) on disposal of fixed assets	23,682	(852,544)	(21,173)
Other income (expense)	228,666	(686,865)	(987,482)
Total other (expense) income	(939,724)	1,238,313	950,264
Net income before income tax expense	27,749,002	16,293,293	22,781,892
(Provision for) benefit from income taxes	(14,388,422)	(6,244,965)	7,961,321
Net income	13,360,580	10,048,328	30,743,213
Net (loss) income attributable to noncontrolling interests	(6,631,563)	3,189,873	(3,841,285)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	19,992,143	6,858,455	34,584,498
Other comprehensive income
Foreign currency translation adjustment	(263,036)	743,699	773,707
Total comprehensive income	$ 19,729,107	$ 7,602,154	$ 35,358,205
Net income per share attributable to DocGo Inc. and Subsidiaries - Basic (in Dollars per share)	$ 0.20	$ 0.07	$ 0.34
Weighted-average shares outstanding - Basic (in Shares)	102,395,141	103,511,299	101,228,369
Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted (in Dollars per share)	$ 0.18	$ 0.06	$ 0.34
Weighted-average shares outstanding - Diluted (in Shares)	109,422,840	105,617,817	102,975,831

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Total	CRMS	FMC NA	Healthwrox	Ambulnz CO	Common Stock	Common Stock CRMS	Common Stock FMC NA	Additional Paid-in- Capital	Additional Paid-in- Capital CRMS	Additional Paid-in- Capital FMC NA	Additional Paid-in- Capital Ambulnz CO	Accumulated Deficit	Accumulated Deficit FMC NA	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interests	Noncontrolling Interests FMC NA	Noncontrolling Interests Healthwrox	Noncontrolling Interests Ambulnz CO
Beginning balance (in shares) at Dec. 31, 2021						100,133,953
Beginning balance at Dec. 31, 2021	$ 227,057,024					$ 10,013			$ 283,161,216				$ (63,556,714)		$ (32,501)	$ 7,475,010
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity cost	(19,570)								(19,570)
Noncontrolling interest contribution	2,063,000															2,063,000
Common stock repurchased (in shares)						(536,839)
Common stock repurchased	(3,731,712)					$ (54)			(3,731,658)
Stock-based compensation	7,183,992								7,183,992
Exercise of stock options (in shares)						1,053,401
Exercise of stock options	1,980,779					$ 105			1,980,674
Cashless exercise of options (in shares)						354,276
Cashless exercise of options	(194)					$ 36			(230)
Restricted stock units	495,579								495,579
Share warrants conversion (in Shares)						1,406,371
Share warrants conversion	12,381,573					$ 141			12,381,432
Net (loss) income attributable to noncontrolling interests	(3,841,285)															(3,841,285)
Foreign currency translation	773,707														773,707
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	34,584,498												34,584,498
Ending balance (in shares) at Dec. 31, 2022						102,411,162
Ending balance at Dec. 31, 2022	$ 278,927,391					$ 10,241			301,451,435				(28,972,216)		741,206	5,696,725
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock repurchased (in shares)	0
UK Ltd. restricted stock	$ 167,175								167,175
Health liquidation	70,284												70,284
Acquisitions (in shares)							117,330	360,145
Acquisitions		$ 1,000,012					$ 12	$ 36		$ 1,000,000	$ (1,432,963)			$ 649,167
Purchase of interests			$ (3,997,716)	$ (1,296,553)													$ (3,213,956)	$ (1,296,553)
Shares withheld for taxes (in shares)						(280,654)
Shares withheld for taxes	(2,308,954)					$ (27)			(2,308,927)
Stock-based compensation (in shares)						975,382
Stock-based compensation	$ 20,403,282					$ 97			20,403,185
Exercise of stock options (in shares)	514,065					465,429
Exercise of stock options	$ 1,414,008					$ 46			1,413,962
Cashless exercise of options (in shares)						6,374
Cashless exercise of options	0					$ 1			(1)
Net (loss) income attributable to noncontrolling interests	3,189,873															3,189,873
Foreign currency translation	743,699														743,699
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	$ 6,858,455												6,858,455
Ending balance (in shares) at Dec. 31, 2023	104,055,168					104,055,168
Ending balance at Dec. 31, 2023	$ 305,170,956					$ 10,406			320,693,866				(21,394,310)		1,484,905	4,376,089
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock repurchased (in shares)						(3,647,342)
Common stock repurchased	(13,756,271)					$ (365)			(13,755,906)
Acquisitions												$ 340,450
Purchase of interests					$ (1,848,000)														$ (2,188,450)
Shares withheld for taxes (in shares)						(297,313)
Shares withheld for taxes	(1,168,877)					$ (30)			(1,168,847)
Stock-based compensation (in shares)						1,205,461
Stock-based compensation	$ 13,137,525					$ 120			13,137,405
Exercise of stock options (in shares)	16,559					16,559
Exercise of stock options	$ 26,330								26,328
CRMS True-up Payment (in shares)						578,350
CRMS True-up Payment	1,814,345					$ 58			1,814,287
Net (loss) income attributable to noncontrolling interests	(6,631,563)															(6,631,563)
Dividends paid to noncontrolling interest	(1,294,422)															(1,294,422)
Foreign currency translation	(263,036)														(263,036)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	$ 19,992,143												19,992,143
Ending balance (in shares) at Dec. 31, 2024	101,910,883					101,910,883
Ending balance at Dec. 31, 2024	$ 315,179,130					$ 10,191			$ 321,087,583				$ (1,402,167)		$ 1,221,869	$ (5,738,346)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 13,360,580	$ 10,048,328	$ 30,743,213
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation expense	5,606,818	4,829,780	4,114,346
Amortization of intangible assets	5,660,818	5,249,358	3,214,814
Amortization of finance lease right-of-use assets	4,617,262	6,352,754	3,236,418
(Gain) loss on disposal of assets	(23,682)	852,544	21,173
Deferred income tax	3,466,505	(1,981,519)	(9,957,967)
Loss (gain) on equity method investments	316,044	343,336	(8,919)
Bad debt expense	5,235,560	3,601,520	3,815,187
Stock-based compensation	13,634,086	20,969,174	8,054,571
Loss (gain) on remeasurement of operating and finance leases	32,363	866	(1,388,273)
Loss on liquidation of business	0	70,284	0
Gain on remeasurement of warrant liabilities	0	0	(1,127,388)	$ (5,200,000)
Gain on bargain purchase	0	0	(1,593,612)
Finite-lived intangible asset impairment	8,306,591	0	0
Goodwill impairment	0	0	2,921,958
Change in fair value of contingent consideration	(9,392,133)	(1,437,525)	0
Changes in operating assets and liabilities:
Accounts receivable	41,272,218	(160,524,934)	(8,415,793)
Asset held for sale	0	0	190,312
Prepaid expenses and other current assets	13,007,231	(10,843,890)	(4,181,035)
Other assets	(1,384,824)	1,059,605	1,557,655
Accounts payable	8,562,006	(1,780,403)	3,637,305
Accrued liabilities	(41,940,373)	58,968,844	(5,964,064)
Net cash provided by (used in) operating activities	70,337,070	(64,221,878)	28,869,901
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(3,834,146)	(7,584,561)	(3,198,234)
Acquisition of intangibles	(2,002,103)	(2,541,661)	(2,299,558)
Acquisition of businesses	0	(20,203,464)	(32,953,179)
Equity method investments	(310,450)	(298,932)	0
Payments to acquire equity securities	(5,000,000)	0	0
Proceeds from disposal of property and equipment	274,427	747,088	3,000
Net cash used in investing activities	(10,872,272)	(29,881,530)	(38,447,971)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line	45,000,000	25,000,000	0
Repayments of revolving credit line	(40,000,000)	0	(25,881)
Repayments of notes payable	(51,987)	(25,926)	(925,151)
Due to seller	(3,118,595)	(13,590,382)	(2,535,521)
Acquisition of noncontrolling interest	(1,848,000)	0	0
Earnout payments on contingent liabilities	(3,608,553)	(5,266,681)	0
Dividends paid to noncontrolling interest	(1,294,422)	0	0
Noncontrolling Interest, Increase from Sale of Parent Equity Interest	0	0	2,063,000
Proceeds from exercise of stock options	26,330	1,581,183	1,980,585
Payments for taxes related to shares withheld for employee taxes	(1,168,877)	(2,308,954)	0
Common stock repurchased	(13,756,271)	0	(3,731,712)
Equity costs	0	0	(19,570)
Payments on obligations under finance lease	(4,334,463)	(4,270,553)	(2,985,568)
Net cash (used in) provided by financing activities	(24,154,838)	1,118,687	(6,179,818)
Effect of exchange rate changes on cash and cash equivalents	(190,639)	1,093,633	761,232
Net increase (decrease) in cash and restricted cash	35,119,321	(91,891,088)	(14,996,656)
Cash and restricted cash at beginning of period	72,217,986	164,109,074	179,105,730
Cash and restricted cash at end of period	107,337,307	72,217,986	164,109,074	179,105,730
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	2,142,288	250,100	197,005
Cash paid for interest on finance lease liabilities	769,041	600,239	559,596
Cash paid for income taxes	7,249,331	4,251,658	1,505,235
Right-of-use assets obtained in exchange for lease liabilities	13,973,620	7,621,538	5,035,201
Remeasurement of finance lease right-of-use asset due to lease modification	300,000	0	0
Fixed assets acquired in exchange for notes payable	0	0	923,377
Supplemental non-cash investing and financing activities:
CRMS True-up Payment through issuance of stock	1,814,345	0	0
Receivable exchanged for trade credits	0	1,500,000	0
Pre-acquisition receivables written off through due to seller	4,675,758	0	0
Reconciliation of cash and restricted cash
Cash	89,241,695	59,286,147	157,335,323
Restricted cash	18,095,612	12,931,839	6,773,751
Total cash and restricted cash shown in statement of cash flows	107,337,307	72,217,986	164,109,074	$ 179,105,730
FMC NA
Supplemental non-cash investing and financing activities:
Acquisition of remaining FMC NA through due to seller and issuance of stock	0	7,000,000	0
CRMS
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Change in fair value of contingent consideration	(9,565,876)	1,265,645
Supplemental non-cash investing and financing activities:
Acquisition of remaining FMC NA through due to seller and issuance of stock	$ 0	$ 1,000,000	$ 0

Description of Organization and

Description of Organization and Business Operations	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Organization and Business Operations	Description of Organization and Business Operations Background Pursuant to the Merger Agreement and as described in the Company’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021, Merger Sub merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation and becoming a wholly owned subsidiary of the Company. Ambulnz was originally formed in Delaware on June 17, 2015 as Ambulnz, LLC, a limited liability company. On November 1, 2017, with an effective date of January 1, 2017, Ambulnz converted its legal structure from a limited liability company to a C-corporation and changed its name to Ambulnz, Inc. Ambulnz is the sole owner of Ambulnz Holdings, LLC (“Holdings”), which was formed in the state of Delaware on August 5, 2015 as a limited liability company. Holdings is the owner of multiple operating entities incorporated in various states in the United States (“U.S.”) as well as within England and Wales, United Kingdom (“U.K.”). The Business The Company is a mobile healthcare services company that uses proprietary dispatch and communication technology to help provide (i) quality mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and (ii) healthcare transportation in major metropolitan cities in the U.S. and the U.K. The Company conducts business in three operating segments: Mobile Health Services, Transportation Services and Corporate. Mobile Health Services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved, population groups primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter. Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities. The Company’s Corporate segment primarily represents shared services and personnel that support both the Mobile Health Services and Transportation Services segments. It contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. None of the Company’s revenues or cost of revenues are reported within the Corporate segment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and applicable rules and regulations of the SEC. Principles of Consolidation The Consolidated Financial Statements include the accounts and operations of DocGo Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI“) on the Consolidated Financial Statements represent a portion of consolidated joint ventures and variable interest entities (“VIEs“) in which the Company does not have direct equity ownership. Certain amounts in the prior years’ Consolidated Statements of Changes in Stockholders’ Equity and Consolidated Statements of Cash Flows have been reclassified to conform to the current year presentation. In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are VIEs. For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. The Company has entered into management services agreements (“MSAs”) with professional corporations (“PCs”) that employ or contract with physicians and other health professionals in order to provide healthcare services to the public. Each such PC is established and operated pursuant to the requirements of its respective domestic jurisdiction governing the practice of medicine. The Company provides each PC with everything the PC needs to operate except for clinicians, which the PC is responsible for. Without the administrative services, software, intellectual property and administrative personnel (among other things) provided by the Company, the PCs could not carry out their businesses. Moreover, the PCs do not have sufficient equity to finance their activities without additional subordinated financial support. Based on the foregoing, these entities are considered VIEs, and an enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is the primary beneficiary, meaning it has (1) the power to direct the activities of the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). In accordance with corporate practice of medicine restrictions, all clinical treatment decisions are made solely by licensed healthcare professionals engaged by the PCs. Nevertheless, the PCs cannot operate without the Company through the MSAs; therefore the Company significantly impacts the economic performance of the PCs and funds and absorbs all losses of its VIEs. The Company has therefore determined that it is the primary economic beneficiary of the PCs and appropriately consolidates them as VIEs. Net loss for the Company’s VIEs wer e $231,952, $235,976 and $373,456 for the years ended December 31, 2024, 2023 and 2022, respectively. The total assets amounted to $20,837,325 an d $4,364,274 on December 31, 2024 and 2023, respectively. Total liabilities were $21,516,860 and $4,811,857 on December 31, 2024 and 2023, respectively. The Company’s VIEs total stockholders’ deficit wer e $679,535 a nd $447,583 on December 31, 2024 and 2023, respectively. Foreign Currency The Company’s functional currency is the U.S. dollar. The functional currency of our foreign operation is the British pound. Assets and liabilities of the Company’s foreign operation denominated in the British pound are translated at the spot rate in effect at the applicable reporting date, except for equity accounts which are translated at historical rates. The Consolidated Statements of Operations and Comprehensive Income are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment for the years ended December 31, 2024, 2023 and 2022 were $(263,036), $743,699, and $773,707, respectively. Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses; the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition related to the allowance for credit loss, stock-based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, contingent consideration, reserve for losses within the Company’s insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations could be adversely affected. Self-Insurance Reserves The Company self-insures a number of risks, including, but not limited to, workers’ compensation, general liability, auto liability and certain employee-related healthcare benefits. Standard actuarial procedures and data analysis are used to estimate the liabilities associated with these risks on an undiscounted basis. The recorded liabilities reflect the ultimate cost for claims incurred but not paid and any estimable administrative run-out expenses related to the processing of these outstanding claim payments. On a regular basis, the liabilities are evaluated for appropriateness with claims reserve valuations. To limit exposure to some risks, the Company maintains insurance coverage with varying limits and retentions, including stop-loss insurance coverage for workers’ compensation, general liability and auto liability. Concentration of Credit Risk and Off-Balance Sheet Risk The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss. Major Customers The Company had one customer that accounted for approximately 38% of revenues and 39% of net accounts receivable and another customer that accounted for 28% of revenues and 37% of net accounts receivable for the year ended December 31, 2024. The Company had one customer that accounted for approximately 40% of revenues and 42% of net accounts receivable and another customer that accounted for 21% of revenues and 40% of net accounts receivable for the year ended December 31, 2023. The Company had one customer that accounted for approximately 35% of revenues and 45% of net accounts receivable for the year ended December 31, 2022. Major Vendor The Company had one vendor that accounted for approximately 17%, 14% and 12% of total cost for the years ended December 31, 2024, 2023 and 2022 , respectively. The Company expects to maintain this relationship with the vendor and believes the services provided from this vendor are available from alternatives sources. Reclassifications Certain reclassifications of amounts previously reported have been made to the accompanying Consolidated Financial Statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net income or retained earnings. Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the U.S. The Company’s accounts at financial institutions in the U.S. are insured by the FDIC and are in excess of FDIC insured limits. The Company had cash balances of approximately $4,020,221 and $3,699,793 with foreign financial institutions on December 31, 2024 and 2023, respectively. Restricted Cash Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for self-insurance exposures, and a standby letter of credit as required by its insurance carrier (see Note 10). The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits. ARM Insurance, Inc., a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures. The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in “Restricted cash” in the accompanying Consolidated Balance Sheets. Fair Value of Financial Instruments ASC 820, Fair Value Measurements , provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2024, December 31, 2023 and December 31, 2022. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses, and due to seller, the carrying amounts approximate their fair values as it is short term in nature. The notes payable are presented at their carrying value, which, based on borrowing rates currently available to the Company for loans with similar terms, approximates its fair values. Contingent Consideration In connection with the acquisition of Ryan Bros. Fort Atkinson, LLC (“Ryan Brothers”), the Company recorded $4,000,000 in contingent consideration to be paid based on the completion of certain performance obligations over a 24-month period. The Company recorded a change in fair value of contingent consideration in the amount of $187,506 and $(338,956) for the years ended December 31, 2024 and 2023, respectively. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2022. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $1,840,026 and paid the remaining $2,008,524 as of December 31, 2024. There was no estimated contingent consideration amount payable for Ryan Brothers as of December 31,2024 and an estimated contingent consideration of $1,821,018 as of December 31, 2023 (see Note 4). In connection with the acquisition of Exceptional Medical Transportation, LLC (“Exceptional”), the Company also agreed to pay up to $2,000,000 in contingent consideration upon meeting certain performance conditions within two years of the closing date of such acquisition. The Company recorded a change in fair value of contingent consideration in the amount of $(13,763) and $(374,044) for the years ended December 31, 2024 and 2023, respectively. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2022. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $426,655. The estimated contingent consideration amount payable for Exceptional was $265,538 and $279,301 as of December 31, 2024 and 2023, respectively (see Note 4). In connection with the acquisition of Location Medical Services, LLC (“LMS”), the Company recorded $2,475,540 in contingent consideration to be paid upon LMS meeting certain performance conditions in 2023. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2024, recorded a change in fair value of contingent consideration in the amount of $(2,000,312) for the year ended December 31, 2023, and did not record a change in fair value of contingent consideration for the year ended December 31, 2022. Additionally, the Company recorded foreign exchange movements of $(4,798) and $129,599 for the years ended December 31, 2024 and 2023, respectively. The Company did not record any foreign exchange movements for the year ended December 31, 2022. On April 2, 2024, the Company paid the remaining contingent consideration balance in the amount of $600,029. There was no remaining contingent liability bal ance as of December 31, 2024 and a contingent liability balance of $604,827 as of December 31, 2023 (see Note 4). In connection with the acquisition of Cardiac RMS, LLC (“CRMS”), the Company recorded $15,822,190 in contingent consideration, consisting of an estimated true-up payment of $2,088,243 to be paid in 2024 based on the attainment of full-year 2023 EBIDTA targets (the “True-Up Payment”) and estimated earn out payments amounting to $13,733,947. The earn out payments are to be paid out over 36 months, beginning in 2025, for the remaining 49% equity of CRMS, based on CRMS’ attainment of full-year EBITDA targets. The Company recorded a change in fair value of contingent consideration in the amount of $(9,565,876) and $1,265,645 for the years ended December 31, 2024 and 2023, respectively. On May 29, 2024, the Company paid a portion of the True-up Payment in the amount of $1,000,000. On July 19, 2024, the Company issued $1,814,345 in common stock, par value $0.0001 (“Common Stock”), or 578,350 shares, constituting the remainder of the True-up Payment. The estimated contingent consideration amount payable for CRMS was $4,707,614 and $17,087,835 as of December 31, 2024 and 2023, respectively (see Note 4). Impairment of Finite-Lived Intangible Assets The Company evaluated its intangible assets as of December 31, 2024 and determined there was an impairment in relation to its customer relationships in CRMS. The impairment is a result of reduced growth expectations and decreases in the estimated future cash flows of the asset group which represented a triggering event that required an evaluation of the underlying finite-lived intangible assets for impairment. The Company used a discounted cash flow analysis to fair value the customer relationships. This calculation contains uncertainties as they require management to make assumptions including, but not limited to, future cash flows of the asset group, an appropriate discount rate, and long-term growth rates. This fair value determination is categorized as Level 3 within the fair value hierarchy. As a result of this impairment, the Company recognized a non-cash impairment charge of $8,306,591 in the year ended December 31, 2024 in the Consolidated Statements of Operations and Comprehensive Income. The charge was recorded as part of other income in the Company’s Consolidated Statements of Operations and Comprehensive Income and has no impact on its cash flow, liquidity or compliance with debt covenants. Refer to Note 7. Equity Investment Without Readily Determinable Fair Value The Company has invested in equity securities without readily determinable fair values and has elected to measure them using the measurement alternative in accordance with ASC 321, Investments - Equity Securities (“ASC 321”). This investment is carried at cost less any impairment and adjusted to fair value if there are observable price changes for an identical or similar investment of the same issuer. Refer to Note 8. Accounts Receivable The Company contracts with hospitals, healthcare facilities, businesses, state and local government entities, and insurance providers to provide Mobile Health Services and Transportation Services at specified rates. These rates are either on a per procedure or per transport basis, or on an hourly or daily basis. Accounts receivable consist of billings for healthcare and transportation services provided to patients. Billings typically are either paid or settled on the patient’s behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs or businesses or patients directly. The Company generally does not require collateral for accounts receivable . Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time of billing based on contractual terms or other arrangements. The Company maintains an allowance for credit losses for accounts receivable, net which is recorded as an offset to accounts receivable, net and changes in this allowance are recorded within general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Income (Loss). The carrying amount of accounts receivable represents the maximum credit risk exposure of these assets. On a quarterly basis, in accordance with Federal Accounting Standards Board (“FASB”) ASC 326, Measurement of Credit Losses on Financial Instruments , the Company evaluates the collectability of outstanding accounts receivable balances to determine an allowance for credit loss that reflects its best estimate of the lifetime expected credit losses. Individual uncollectible accounts are written off against the allowance when collection of the individual account does not appear probable. Under the current expected credit loss impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on a single portfolio segment. The Company assesses collectability by aggregating and reviewing accounts receivable on a collective basis for customers that share similar risk characteristics. Additionally, when accounts receivable do not share risk characteristics with other accounts receivables, management will evaluate such accounts receivable for expected credit loss on an individual specific identification basis when the Company identifies specific customers with known disputes or collectability issues. Due to the short-term nature of the Company’s accounts receivables, the estimate of expected credit loss is based on the aging of accounts using an aging schedule as of period ends. In determining the amount of the allowance for credit losses, the Company considers historical collection history based on past due status, the current aging of receivables, customer-specific credit risk factors including their current financial condition, current market conditions, and probable future economic conditions which inform adjustments to historical loss patterns. As of January 1, 2024, the Company held a beginning balance in its allowance for credit losses on accounts receivable of $6,276,454. The Company recognized an additional provision for credit losses of $4,384,866 and write offs of $(4,787,379) during the year. The Company’s balance in its allowance for credit losses amounted to $5,873,942 as of December 31, 2024 . Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the Consolidated Statements of Operations and Comprehensive Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows: Estimated Useful Life Buildings 39 years Office equipment and furniture 3-7 years Vehicles 5-8 years Medical equipment 5 years Leasehold improvements Shorter of useful life of asset or lease term Expenditures for repairs and maintenance are charged to expense as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized. Software Development Costs Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software . Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life. Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality. Business Combinations The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations. The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values. Impairment of Long-Lived Assets The Company evaluates the recoverability of the recorded amount of long-lived assets, primarily property and equipment and finite-lived intangible assets, whenever events or changes in circumstance indicate that the recorded amount of an asset may not be fully recoverable. An impairment is assessed when the undiscounted expected future cash flows derived from an asset are less than its carrying amount. If an asset is determined to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. Assets targeted for disposal are reported at the lower of the carrying amount or fair value less cost to sell. Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization, as indicated by its publicly quoted share price, below its net book value. Line of Credit The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense. Interest expense on outstanding balances is expensed as incurred. Derivative Liabilities The Company does not use derivative instruments to hedge exposures to interest rate, market or foreign currency risks. The Company evaluates its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Related Party Transactions The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, members of immediate families of principal owners or management, and other parties with which the Company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Related party transactions are recorded within operating expenses in the Consolidated Statements of Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the years ended December 31, 2024, 2023 and 2022 refer to Note 18. Revenue Recognition On January 1, 2019, the Company adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”). To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer. The Company generates revenues from the provision of (1) Mobile Health Services and (2) Transportation Services. Since the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. The transaction price associated with the Company’s contracts with customers is generally determined based on fixed and determinable amounts of consideration as specified in a contract, which includes a fixed base rate and/or fixed mileage rate. For Transportation Services arrangements with billings to third party payors and healthcare facilities, this may also include variable consideration in instances where it is considered probable that a significant reversal of cumulative revenue recognized will not occur. For these services, revenues are recorded net of estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowance at the time of billing based on contractual terms, historical collections or other arrangements. The Company also estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company utilizes the expected value method when estimating its variable consideration. The assumptions utilized in estimating variable consideration include the Company’s previous experience with similar contracts and history of collection rates on prior trips that have been performed. The Company reevaluates its variable consideration at each reporting period. Nature of the Company’s Services Revenue is primarily derived from: i. Mobile Health Services : These services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter. ii. Transportation Services : These services encompass both emergency response and non-emergency transport services. Non-emergency transpor

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net as of December 31, 2024 and 2023 are as follows: December 31, December 31, Transportation equipment $ 17,300,595 $ 17,438,072 Medical equipment 9,210,203 7,104,161 Office equipment and furniture 4,293,100 3,701,657 Leasehold improvements 1,239,089 709,619 Buildings 527,283 527,283 Land 37,800 37,800 32,608,070 29,518,592 Less: Accumulated depreciation (17,726,659) (12,683,108) Property and equipment, net $ 14,881,411 $ 16,835,484 During the year ended December 31, 2024, the Company disposed of assets with a cost of $758,859 and accumulated depreciation of $509,378 for proceeds of $274,427. The Company recorded a gain on disposal of assets of $24,946. During the year ended December 31, 2023, the Company disposed of assets with a cost of $12,343,547 and accumulated depreciation of $10,743,915 for proceeds of $747,088. The Company recorded a loss on disposal of assets of $852,544. During the year ended December 31, 2022, the Company disposed of assets with a cost of $50,353 and accumulated depreciation of $26,180 for proceeds of $3,000. The Company recorded a loss on disposal of assets of $21,173. The Company recorded depreciation expenses of $5,606,818, $4,829,780 and $4,114,346 as of December 31, 2024, 2023 and 2022, respectively.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions Exceptional Medical Transportation, LLC On July 13, 2022, Holdings acquired 100% of the outstanding shares of common stock of Exceptional, a provider of medical transportation services, in exchange for $13,708,333 consisting of $7,708,333 in cash at closing and $6,000,000 payable over a 24-month period following the closing date of the acquisition. The Company also agreed to pay up to $2,000,000 in contingent consideration upon meeting certain performance conditions within two years of the closing date of such acquisition. During the year ended December 31, 2024, the Company wrote off $1,315,691 and paid $109,619 of pre-acquisition accounts receivable through due to seller, the liability established during acquisition. Additionally, the Company paid $3,000,000 of the $6,000,000 remaining purchase price payable as of December 31, 2023 and paid the remaining $3,000,000 as of December 31, 2024. There was no remaining purchase price payable as of December 31, 2024 and a purchase price payable of $3,000,000 as of December 31, 2023. As of December 31, 2024 and 2023, there were remaining due to seller balances pertaining to pre-acquisition accounts receivable of $28,656 and $1,453,966, respectively. The Company recorded a change in fair value of contingent consideration in the amount of $(13,763) and $(374,044) for the years ended December 31, 2024 and 2023, respectively. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2022. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $426,655. The estimated contingent consideration amount payable for Exceptional was $265,538 and $279,301 as of December 31, 2024 and 2023, respectively. Ryan Bros. Fort Atkinson, LLC On August 9, 2022, the Company acquired 100% of the outstanding shares of common stock of Ryan Brothers, a provider of medical transportation services, in exchange for an aggregate purchase price of $11,422,252 consisting of $7,422,252 in cash at closing and an estimated $4,000,000 in contingent consideration to be paid out over 24 months, commencing on August 1, 2022, based on performance of certain obligations. During the year ended December 31, 2024, the Company wrote off $3,360,067 pre-acquisition accounts receivable through due to seller, the liability established during acquisition. Additionally, the Company made payments in the amount of $8,976 on the remaining purchase price payable during the year ended December 31, 2024. There was no remaining due to seller balance as of December 31, 2024 and a due to seller balance of $3,369,043 as of December 31, 2023. The Company recorded a change in fair value of contingent consideration in the amount of $187,506 and $(338,956) for the years ended December 31, 2024 and 2023, respectively. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2022. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $1,840,026 and paid the remaining $2,008,524 as of December 31, 2024. There was no estimated contingent consideration amount payable for Ryan Brothers as of December 31,2024 and an estimated contingent consideration of $1,821,018 as of December 31, 2023. Location Medical Services, LLC On December 9, 2022, Holdings, through its indirect wholly owned subsidiary Ambulnz U.K. Ltd. (“UK Ltd.”), acquired 100% of the outstanding shares of common stock of LMS. The aggregate purchase price consisted of $302,450 in cash consideration. The Company also agreed to pay LMS an additional $11,279,201 in deferred consideration and an estimated $2,475,540 in contingent consideration upon LMS meeting certain performance conditions in 2023. Additionally, the Company paid $11,279,201 of deferred consideration to LMS during the year ended December 31, 2023. As of December 31, 2024 and 2023, there was no remaining due to seller amounts outstanding. The Company did not record a change in fair value of contingent consideration for the year ended December 31, 2024, recorded a change in fair value of contingent consideration in the amount of $(2,000,312) for the year ended December 31, 2023, and did not record a change in fair value of contingent consideration for the year ended December 31, 2022. Additionally, the Company recorded foreign exchange movements of $(4,798) and $129,599 for the years ended December 31, 2024 and 2023, respectively. The Company did not record any foreign exchange movements for the year ended December 31, 2022. On April 2, 2024, the Company paid the remaining contingent consideration balance in the amount of $600,029. There was no remaining contingent liability balance as of December 31, 2024 and a contingent liability balance of $604,827 as of December 31, 2023. Cardiac RMS, LLC On March 31, 2023, Holdings acquired 51% of the outstanding shares of common stock of CRMS, a provider of cardiac implantable electronic device remote monitoring and virtual care management services. The closing consideration of $10,000,000 consisted of $9,000,000 in cash and $1,000,000 worth of shares of Common Stock issued in a private placement transaction. The Company also agreed to pay additional consideration following the initial closing, consisting of an estimated True-up Payment of $2,088,243 to be paid in 2024 based on the attainment of full-year 2023 EBITDA targets and estimated earn out payments amounting to $13,733,947. The earn out payments are to be paid out over 36 months, beginning in 2025, for the remaining 49% equity of CRMS, based on CRMS’ attainment of full-year EBITDA targets. $5,000,000 of such further probable consideration is to be paid in cash and the remaining $10,822,190 is to be paid in shares of Common Stock. Acquisition costs are included in general and administrative expenses and totaled $229,937 for the year ended December 31, 2023. The Company recorded a change in fair value of contingent consideration in the amount of $(9,565,876) and $1,265,645 for the years ended December 31, 2024 and 2023, respectively. On May 29, 2024, the Company paid a portion of the True-up Payment in the amount of $1,000,000. On July 19, 2024, the Company issued $1,814,345 in Common Stock, or 578,350 shares, constituting the remainder of the True-up Payment. The estimated contingent consideration amount payable for CRMS was $4,707,614 and $17,087,835 as of December 31, 2024 and 2023, respectively. Ambulnz-FMC North America LLC On April 1, 2023, the Company acquired the remaining outstanding shares of common stock of Ambulnz-FMC North America LLC (“FMC NA”), a prominent healthcare company that focuses on providing vital products and services for patients suffering from kidney diseases and renal failure, from its joint venture with Holdings in exchange for $4,000,000 in cash and $3,000,000 in Common Stock. Acquisition costs are included in general and administrative expenses totaling approximately $35,560 for the year ended December 31, 2023. Healthworx LLC On May 10, 2023, the Company acquired the remaining outstanding shares of common stock of Healthworx LLC (“Healthworx”), a provider of management, administration and support services to service providers focused on medical testing and diagnostic screening, from its joint venture with Rapid Reliable Testing, LLC (“RRT”) in exchange for $1,385,156 in cash. Ambulnz CO, LLC On July 1, 2024, the Company acquired the remaining noncontrolling interest in its Ambulnz CO, LLC (“Ambulnz CO”) joint venture from the University of Colorado Health in exchange for $1,848,000 in cash. The following table presents the assets acquired and liabilities assumed at the date of the acquisitions: Ambulnz CO FMC NA CRMS Total Consideration: Cash consideration $ 1,848,000 $ 4,000,000 $ 9,000,000 $ 14,848,000 Stock consideration — 3,000,000 1,000,000 4,000,000 Due to seller — — — — Amounts held under an escrow account — — — — Contingent liability — — 15,822,190 15,822,190 Total consideration $ 1,848,000 $ 7,000,000 $ 25,822,190 $ 34,670,190 Recognized amounts of identifiable assets acquired and liabilities assumed Cash $ — $ — $ 1,574,604 $ 1,574,604 Accounts receivable — — 2,033,533 2,033,533 Other current assets — — 293,478 293,478 Property and equipment — — — — Intangible assets — — 15,930,000 15,930,000 Total identifiable assets acquired — — 19,831,615 19,831,615 Accounts payable — — 28,978 28,978 Due to seller — — 2,448,460 2,448,460 Other current liabilities — — 174,177 174,177 Total liabilities assumed — — 2,651,615 2,651,615 Noncontrolling interests 2,188,450 2,567,037 — 4,755,487 Goodwill — — 8,642,190 8,642,190 Additional paid-in-capital (340,450) 4,432,963 — 4,092,513 Total purchase price $ 1,848,000 $ 7,000,000 $ 25,822,190 $ 34,670,190 Pro Forma Disclosures The following unaudited pro forma combined financial information for the fiscal years ended December 31, 2023 and 2022 gives effect to the acquisitions disclosed above as if they had occurred on January 1, 2022. The pro forma information is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. The figures presented below for the year ended December 31, 2023 represent the actual results of the Company, as the financial results of CRMS were consolidated in the Company’s results of operations for the entirety of the period. 2023 2022 Revenue $ 627,402,261 $ 539,522,587 Net income $ 11,087,122 $ 46,960,359 The unaudited pro forma combined financial information presented above includes the accounting effects of the acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; depreciation of property and equipment that have been revalued; transaction costs; interest expense; and the related tax effects.

ABC Transaction and Held for Sa

ABC Transaction and Held for Sale	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
ABC Transaction and Held for Sale	ABC Transaction and Held for Sale In 2022, the Company started discussions regarding the potential liquidation process of Ambulnz Health, LLC (“Health”) through an assignment for the benefit of creditors (“ABC”), with a targeted timeline for the transaction to be fully closed by December 31, 2022. The conversation involved operations, human resources, external legal counsel, and Amb, LLC, a California limited liability company (the “Assignee”). Due to operational processes, the filing was extended and finalized on February 3, 2023. An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health’s assets were transferred to the Assignee, who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there is a claims process. Creditors of Health received notice of the ABC and a proof of claim form and were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee. As of December 31, 2022, Health met the criteria to be classified as held for sale. A s a result, the Company was required to record the respective assets and liabilities at the lower of carrying value or fair value, less any costs to sell and present the related assets and liabilities as separate line items in the Consolidated Balance Sheets. The intercompany receivables and intercompany payables were eliminated in the Company’s Consolidated Balance Sheet as of December 31, 2022.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill In connection with the ABC, the Company evaluated its goodwill balances as of December 31, 2022 and determined that there was an impairment of goodwill related to its Health reporting unit. The impairment was primarily due to the ABC filing. As a result of this impairment, the Company recognized a non-cash charge of $2,921,958 in the year ended December 31, 2022 in the Consolidated Statements of Operations and Comprehensive Income. The charge was recorded as part of other income in the Company’s Consolidated Statements of Operations and Comprehensive Income and has no impact on its cash flow, liquidity or compliance with debt covenants. The Company did not record any goodwill in connection with acquisitions during the year ended December 31, 2024. The Company recorded an aggregate of $8,642,190 in goodwill in connection with its acquisitions during the year ended December 31, 2023. Carrying Value Balance as of December 31, 2022 $ 38,900,413 Goodwill acquired during the period 8,642,190 Currency translation adjustment and others (2,674) Balance as of December 31, 2023 $ 47,539,929 Currency translation adjustment and others (107,379) Balance as of December 31, 2024 $ 47,432,550

Intangibles

Intangibles	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	Intangibles Intangible assets consisted of the following as of December 31, 2024 and 2023: December 31, 2024 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (242,059) $ 5,769 Operating licenses Indefinite 9,399,004 — — — 9,399,004 Internally developed software 4-5 years 10,078,087 2,051,826 — (11,227,960) 901,953 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 28,337,524 (37,400) (8,306,591) (6,504,390) 13,489,143 Trademark 8-15 years 427,531 (21,999) — (100,138) 305,394 Non-compete agreements 5 years 100,000 — — (35,000) 65,000 Trade credits 5 years 1,500,000 — — — 1,500,000 $ 50,152,524 $ 1,992,427 $ (8,306,591) $ (18,109,547) $ 25,728,813 December 31, 2023 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (235,967) $ 11,861 Operating licenses Indefinite 8,799,004 600,000 — — 9,399,004 Internally developed software 4-5 years 8,284,058 1,794,029 — (8,821,563) 1,256,524 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 12,397,954 15,939,570 — (3,334,925) 25,002,599 Trademark 8-15 years 389,469 38,062 — (62,141) 365,390 Non-compete agreements 5 years — 100,000 — (15,000) 85,000 Trade credits 5 years — 1,500,000 — — 1,500,000 $ 30,180,863 $ 19,971,661 $ — $ (12,469,596) $ 37,682,928 The intangible assets include an immaterial foreign currency translation adjustment in the amount of $(12,455) for the year ended December 31, 2024. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. During the year ended December 31, 2024, the Company disposed of intangible assets with a cost of $1,540 and accumulated amortization of $276. The Company recorded a loss on disposal of intangible assets of $1,264 for the year ended December 31, 2024. There were no disposal of intangible assets for the years ended December 31, 2023 and 2022. The Company also reclassified certain intangible assets with a cost of $30,361 and accumulated amortization of $8,136 to “legal and regulatory” expenses within the Consolidated Statements of Operations and Comprehensive Income. The Company evaluated its intangible assets as of December 31, 2024 and determined there was an impairment in relation to its customer relationships in CRMS. The impairment is a result of reduced growth expectations and decreases in the estimated future cash flows of the asset group which represented a triggering event that required an evaluation of the underlying finite-lived intangible assets for impairment. The Company used a discounted cash flow analysis to fair value the customer relationships. This calculation contains uncertainties as they require management to make assumptions including, but not limited to, future cash flows of the asset group, an appropriate discount rate, and long-term growth rates. This fair value determination is categorized as Level 3 within the fair value hierarchy. As a result of this impairment, the Company recognized a non-cash impairment charge of $8,306,591 in the year ended December 31, 2024 in the Consolidated Statements of Operations and Comprehensive Income. The charge was recorded as part of other income in the Company’s Consolidated Statements of Operations and Comprehensive Income and has no impact on its cash flow, liquidity or compliance with debt covenants. The Company recorded amortization expense of $5,660,818, $5,249,358 and $3,214,814 for the periods ended December 31, 2024, 2023 and 2022, respectively. Future amortization expense at December 31, 2024 for the next five years and in the aggregate are as follows: Amortization 2025 $ 2,839,672 2026 2,167,093 2027 2,149,822 2028 2,113,652 2029 2,080,148 Thereafter 3,416,872 Total $ 14,767,259

Investments

Investments	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments The Company’s ownership interest and carrying amounts of investments as of December 31, 2024 and 2023 consist of the following: December 31, December 31, Percentage Ownership Amount Percentage Ownership Amount Equity investment without readily determinable fair value $ 5,000,000 $ — Equity method investment Various 547,979 Various 553,573 Total investments $ 5,547,979 $ 553,573 Equity Investment without Readily Determinable Fair Value On October 25, 2024, the Company acquired non-marketable equity securities in Firefly Health, Inc for $5,000,000. These investments are measured at cost, less any impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. During the year ended 2024, no impairment losses or upward adjustments were recognized for the equity investments without readily determinable fair value. As of December 31, 2024, the Company’s investments in equity securities without readily determinable fair values totaled $5,000,000, and are included in the caption “Investments” on the Consolidated Balance Sheets. Equity Method Investments On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. (“RND”) for $655,876. During the year ended December 31, 2024 and 2023, the Company made an additional investment amounting to $310,450 and $298,932, respectively. The Company’s carrying value in RND, an equity method investee, is reflected in the caption “Investments” on the Consolidated Balance Sheets. Changes in value of RND are recorded in “(Loss) gain on equity method investments” on the accompanying Consolidated Statements of Operations and Comprehensive Income.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2024
Accrued Liabilities [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following at the dates indicated: December 31, December 31, Accrued workers' compensation and other insurance liabilities $ 16,738,835 $ 12,881,902 Accrued general expenses 13,924,809 27,001,232 Accrued subcontractors 9,174,499 37,858,755 Accrued payroll 4,374,654 6,464,192 Accrued bonus 3,078,445 4,784,005 Other current liabilities 2,605,554 2,350,523 Total accrued liabilities $ 49,896,796 $ 91,340,609

Line of Credit

Line of Credit	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Line of Credit	Line of Credit On November 1, 2022, the Company entered into a credit agreement (the “Credit Agreement”) with two banks, with one bank in the capacity as a lender and the administrative agent (collectively with the other lender, the “Lenders”). The Credit Agreement provides for a revolving credit facility in the initial aggregate principal amount of $90,000,000 (the “Revolving Facility”). The Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to $50,000,000, though no Lender (nor the Lenders collectively) is obligated to increase its respective commitments. Borrowings under the Revolving Facility bear interest at a per annum rate equal to: (i) at the Company’s option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins were 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and are updated based on the Company’s consolidated net leverage ratio. The Revolving Facility matures on the five-year anniversary of the closing date, November 1, 2027. The Revolving Facility is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets. The Revolving Facility is subject to certain financial covenants such as a net leverage ratio and interest coverage ratio, as defined in the Credit Agreement. As of December 31, 2023, there was a $25,000,000 outstanding balance on the Revolving Facility. The Company drew down an additional $15,000,000 on February 8, 2024 under the Revolving Facility. On February 27, 2024, the Company paid the $40,000,000 Revolving Facility balance. On March 4, 2024, the Company drew down $15,000,000 and made an additional $15,000,000 draw on March 18, 2024 . As of December 31, 2024 , the outstanding balance of the Revolving Facility w as $30,000,000 and the unused portion of the Revolving Facility was $60,000,000. The Company incurred $2,162,753 and $359,330 in interest charges relating to its Revolving Facility for the years ended December 31, 2024 and 2023, respectively, which is reflected in interest (expense) income on the Company’s Consolidated Statements of Operations and Comprehensive Income. Standby Letters of Credit On October 20, 2023, the Company obtained an unconditional and irrevocable letter of credit from a financial institution in the amount of $1,080,000. The letter of credit had an initial one-year term, and is renewed automatically for successive one-year periods, unless earlier terminated by the institution. The letter of credit automatically renewed on October 20, 2024. As of December 31, 2024, no amounts had been drawn. On December 20, 2024, the Company obtained an irrevocable letter of credit from a financial institution in the amount of $133,303. The letter of credit expires on the one-year anniversary of the closing date, or December 20, 2025 and is renewed automatically for successive one-year periods, unless earlier terminated by the institution. As of December 31, 2024, no amounts had been drawn. The Company has various loans with finance companies with monthly installments aggregating $1,082, inclusive of interest ranging from 2.5% to 4.8%. The loan notes mature at various times through 2026 and are secured by transportation equipment. During the year ended December 31, 2024, the Company fully repaid one of its loan payables that was originally scheduled to mature in August 2026 amounting to $38,949. As of December 31, 2024, the Company has one remaining loan payable, scheduled to mature in May 2026, with an outstanding balance of $17,730. The following table summarizes the Company’s notes payable: December 31, December 31, Equipment and financing loans payable, between 2.5% and 4.8% interest and maturing on May 2026 and August 2026 $ 17,730 $ 69,717 Total notes payable 17,730 69,717 Less: current portion of notes payable 12,515 28,131 Total non-current portion of notes payable $ 5,215 $ 41,586 Interest expenses were $3,407, $(201,883) and $117,664 for the periods ended December 31, 2024, 2023 and 2022, respectively. Future minimum annual maturities of notes payable as of December 31, 2024 are as follows: Notes Payable 2025 $ 12,515 2026 5,215 Total maturities 17,730 Current portion of notes payable (12,515) Long-term portion of notes payable $ 5,215

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	Line of Credit On November 1, 2022, the Company entered into a credit agreement (the “Credit Agreement”) with two banks, with one bank in the capacity as a lender and the administrative agent (collectively with the other lender, the “Lenders”). The Credit Agreement provides for a revolving credit facility in the initial aggregate principal amount of $90,000,000 (the “Revolving Facility”). The Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to $50,000,000, though no Lender (nor the Lenders collectively) is obligated to increase its respective commitments. Borrowings under the Revolving Facility bear interest at a per annum rate equal to: (i) at the Company’s option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins were 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and are updated based on the Company’s consolidated net leverage ratio. The Revolving Facility matures on the five-year anniversary of the closing date, November 1, 2027. The Revolving Facility is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets. The Revolving Facility is subject to certain financial covenants such as a net leverage ratio and interest coverage ratio, as defined in the Credit Agreement. As of December 31, 2023, there was a $25,000,000 outstanding balance on the Revolving Facility. The Company drew down an additional $15,000,000 on February 8, 2024 under the Revolving Facility. On February 27, 2024, the Company paid the $40,000,000 Revolving Facility balance. On March 4, 2024, the Company drew down $15,000,000 and made an additional $15,000,000 draw on March 18, 2024 . As of December 31, 2024 , the outstanding balance of the Revolving Facility w as $30,000,000 and the unused portion of the Revolving Facility was $60,000,000. The Company incurred $2,162,753 and $359,330 in interest charges relating to its Revolving Facility for the years ended December 31, 2024 and 2023, respectively, which is reflected in interest (expense) income on the Company’s Consolidated Statements of Operations and Comprehensive Income. Standby Letters of Credit On October 20, 2023, the Company obtained an unconditional and irrevocable letter of credit from a financial institution in the amount of $1,080,000. The letter of credit had an initial one-year term, and is renewed automatically for successive one-year periods, unless earlier terminated by the institution. The letter of credit automatically renewed on October 20, 2024. As of December 31, 2024, no amounts had been drawn. On December 20, 2024, the Company obtained an irrevocable letter of credit from a financial institution in the amount of $133,303. The letter of credit expires on the one-year anniversary of the closing date, or December 20, 2025 and is renewed automatically for successive one-year periods, unless earlier terminated by the institution. As of December 31, 2024, no amounts had been drawn. The Company has various loans with finance companies with monthly installments aggregating $1,082, inclusive of interest ranging from 2.5% to 4.8%. The loan notes mature at various times through 2026 and are secured by transportation equipment. During the year ended December 31, 2024, the Company fully repaid one of its loan payables that was originally scheduled to mature in August 2026 amounting to $38,949. As of December 31, 2024, the Company has one remaining loan payable, scheduled to mature in May 2026, with an outstanding balance of $17,730. The following table summarizes the Company’s notes payable: December 31, December 31, Equipment and financing loans payable, between 2.5% and 4.8% interest and maturing on May 2026 and August 2026 $ 17,730 $ 69,717 Total notes payable 17,730 69,717 Less: current portion of notes payable 12,515 28,131 Total non-current portion of notes payable $ 5,215 $ 41,586 Interest expenses were $3,407, $(201,883) and $117,664 for the periods ended December 31, 2024, 2023 and 2022, respectively. Future minimum annual maturities of notes payable as of December 31, 2024 are as follows: Notes Payable 2025 $ 12,515 2026 5,215 Total maturities 17,730 Current portion of notes payable (12,515) Long-term portion of notes payable $ 5,215

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Derivative Liabilities For the year ended December 31, 2021, the Company determined the fair value of its warrants that were previously publicly traded in active markets (“Public Warrants’) using quoted market prices for identical instruments. Accordingly, the Public Warrants were classified as Level 1 financial instruments. As of December 31, 2021, there were 3,833,333 Public Warrants outstanding at a fair value of $8.1 million. Because the transfer of the Company’s warrants that were issued in a private placement simultaneously with the closing of its initial public offering (“Private Warrants” and together with the Public Warrants, the “warrants”) to anyone outside of a small group of individuals constituting the sponsors of the Company would result in the Private Warrants having substantially the same terms as the Public Warrants, management determined that the fair value of each Private Warrant was the same as that of a Public Warrant, with an insignificant adjustment for marketability restrictions. Accordingly, the Private Warrants were classified as Level 1 financial instruments. As of December 31, 2021, 2,533,333 Private Warrants remained outstanding at a fair value of $5.4 million. Due to fair value changes throughout the year ended December 31, 2021, we recorded a gain on remeasurement of warrant liabilities of $5.2 million. For the year ended December 31, 2022, the Company recorded a gain of approximately $1.1 million from the remeasurement of warrant liabilities. The warrants were marked-to-market in each reporting period, and this loss reflected the increase in the Company’s stock price relative to the beginning of the period. On August 15, 2022, the Company announced the redemption of all of its outstanding warrants under the Warrant Agreement, dated as of October 14, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, on the redemption date of September 16, 2022 (the “Redemption Date”). Warrants surrendered for exercise on a cashless basis resulted in the issuance of 1,406,371 shares of Common Stock. A total of 68,514 warrants were not surrendered on the Redemption Date and were redeemed for $0.10 per warrant. There were no warrants liabilities outstanding for the years ended December 31, 2024, 2023 and 2022.

Business Segment Information

Business Segment Information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information The Company conducts business in three operating segments: Mobile Health Services, Transportation Services, and Corporate. In accordance with ASC 280, Segment Reporting , operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, the Company’s Chief Executive Officer and Chief Financial Officer, in deciding how to allocate resources and assessing performance. Prior to 2023, the Company reported in two segments because the Company’s entities have two main revenue streams. Beginning with the first quarter of 2023, the Company began reporting in three operating segments, adding a Corporate segment to allow for analysis of shared services and personnel that support both the Transportation Services and Mobile Health Services segments. Previously, these costs had been allocated almost entirely to the Transportation Services segment. All of the Company’s revenues and costs of revenues continue to be reported within the Transportation Services and Mobile Health Services segments. The Corporate segment contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. The segment reporting for the prior-year period has been adjusted to conform to the new methodology, for the purposes of allowing a clearer analysis of year-over-year performance. The Company’s Chief Executive Officer and Chief Financial Officer evaluate the Company’s financial information and resources and assesses the performance of these resources by revenue stream and by operating income or loss performance. In accordance with ASU 2023-07, the Company has also included disclosure in the tables below about the significant expense categories that are regularly provided to the chief operating decision maker. The Company has also disclosed an amount for other segment items, which are amounts included in income (loss) from operations that are not regularly provided to the chief operating decision maker. Other segment items primarily consist of technology and development expenses, legal and professional fees, medical supplies, and other general and administrative expenses such as management fees, occupancy expense, and insurance costs. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Mobile Health Services, Transportation Services, and Corporate segments based primarily on results of operations. Operating results for the business segments of the Company are as follows: Mobile Health Transportation Corporate Total Year Ended December 31, 2024 Revenues $ 423,126,040 $ 193,429,092 $ — $ 616,555,132 Significant Segment Expenses 248,887,401 157,386,875 38,938,940 445,213,216 Personnel costs 115,480,700 120,548,486 34,009,595 270,038,781 Subcontractor costs 125,495,305 19,463,199 4,929,345 149,887,849 Vehicle costs 7,911,396 17,375,190 — 25,286,586 Other segment items 80,212,789 38,087,398 24,353,003 142,653,190 Income (loss) from operations 94,025,850 (2,045,181) (63,291,943) 28,688,726 Depreciation and amortization expense 4,770,367 8,305,049 2,809,482 15,884,898 Stock compensation 6,033,516 274,207 7,326,363 13,634,086 Finite-lived intangible asset impairment 8,306,591 — — 8,306,591 Change in fair value of contingent consideration (9,392,133) — — (9,392,133) Total assets 208,739,901 134,169,086 112,712,145 455,621,132 Long-lived assets 36,515,356 68,846,225 9,977,190 115,338,771 Capital expenditures 2,815,218 9,324,171 2,179,585 14,318,974 Year Ended December 31, 2023 Revenues $ 442,793,537 $ 181,495,105 $ — $ 624,288,642 Significant Segment Expenses 283,980,203 146,950,131 44,139,528 475,069,862 Personnel costs 122,233,677 116,689,011 40,156,572 279,079,260 Subcontractor costs 155,134,128 15,380,523 3,982,956 174,497,607 Vehicle costs 6,612,398 14,880,597 — 21,492,995 Other segment items 78,450,514 31,003,597 24,709,689 134,163,800 Income (loss) from operations 80,362,820 3,541,377 (68,849,217) 15,054,980 Depreciation and amortization expense 4,226,657 9,393,895 2,811,340 16,431,892 Stock compensation 1,698,350 1,434,505 17,836,319 20,969,174 Finite-lived intangible asset impairment — — — — Change in fair value of contingent consideration (1,437,525) — — (1,437,525) Total assets 280,646,925 132,178,214 77,626,818 490,451,957 Long-lived assets 32,841,680 78,848,587 11,952,528 123,642,795 Capital expenditures 30,163,882 20,254,373 597,283 51,015,538 Year Ended December 31, 2022 Revenues $ 325,891,440 $ 114,624,306 $ — $ 440,515,746 Significant Segment Expenses 189,978,467 102,697,543 33,409,491 326,085,501 Personnel costs 95,636,747 81,851,310 31,055,130 208,543,187 Subcontractor costs 83,158,899 8,236,644 2,354,361 93,749,904 Vehicle costs 11,182,821 12,609,589 — 23,792,410 Other segment items 43,202,810 26,472,934 22,922,873 92,598,617 Income (loss) from operations 92,710,163 (14,546,171) (56,332,364) 21,831,628 Depreciation and amortization expense 1,685,114 6,050,265 2,830,199 10,565,578 Stock compensation 1,425,299 1,415,670 5,213,602 8,054,571 Finite-lived intangible asset impairment — — — — Change in fair value of contingent consideration — — — — Total assets 116,821,500 118,627,613 157,828,515 393,277,628 Long-lived assets 33,181,594 65,580,291 2,479,889 101,241,774 Capital expenditures 39,569,802 52,105,196 2,542,854 94,217,852 Long-lived assets include property and equipment, goodwill, intangible assets, operating lease right-of-use assets and finance lease right-of-use assets. Geographic Information The following table summarizes Long-lived assets by geographic location for the years ended December 31, 2024, 2023, and 2022: December 31, 2024 2023 2022 Primary Geographical Markets U.S. $ 96,380,597 $ 103,779,506 $ 83,145,362 U.K. 18,958,174 19,863,289 18,096,412 Total long-lived assets $ 115,338,771 $ 123,642,795 $ 101,241,774 Revenues by geographic location are included in Note 2.

Equity

Equity	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Equity	Equity Unregistered Sales of Equity Securities On July 19, 2024, in connection with the CRMS acquisition, the Company issued $1,814,345 in Common Stock, or 578,350 shares, constituting the remainder of the True-up Payment. The True-up Payment was based on CRMS’ attainment of full-year EBITDA targets for 2023 (see Note 4). Share Repurchase Program On May 24, 2022, the Company’s Board of Directors (the “Board of Directors” or the “Board”) authorized a share repurchase program to purchase up to $40,000,000 of Common Stock (the “2022 Repurchase Program”). During the second and fourth quarter of 2022, the Company repurchased 536,839 shares of its Common Stock for $3,731,712. These shares were subsequently cancelled. The 2022 Repurchase Program, which did not oblige the Company to repurchase a specific number of shares, expired on November 24, 2023. On January 30, 2024, the Board of Directors authorized a new share repurchase program to purchase up to $36,000,000 in shares of Common Stock during a six-month period that ended July 30, 2024 (the “Prior Repurchase Program”). The Prior Repurchase Program did not obligate the Company to repurchase a specific number of shares. On August 5, 2024, following the expiration of the previously authorized share repurchase program on July 30, 2024, the Board effectively extended the Prior Repurchase Program by authorizing a new share repurchase program (the “New Repurchase Program”) on the same terms and conditions as the Prior Repurchase Program other than expiration, pursuant to which the Company may purchase up to $26,000,000 in shares of Common Stock, which was the approximate amount remaining under the Prior Repurchase Program at its expiration. The New Repurchase Program was originally set to expire on December 31, 2024. On December 20, 2024, the Board of Directors extended the expiration date of the New Repurchase Program from December 31, 2024 to June 30, 2025. Under the terms of the New Repurchase Program, the Company may purchase shares of Common Stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information. The timing, manner, price and amount of shares repurchased under the New Repurchase Program depends on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The New Repurchase Program may be modified, suspended or discontinued at any time without prior notice. Repurchases under the New Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings. During the year ended December 31, 2024, the Company repurchased and subsequently cancelled 3,647,342 shares of Common Stock for $13,756,271. There were no shares repurchased during the year ended December 31, 2023.

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation	Stock Based Compensation Stock Options In 2021, the Company established the DocGo Inc. 2021 Equity Incentive Plan (the “Plan”) replacing Ambulnz, Inc.’s 2017 Equity Incentive Plan. The Plan reserved 16,607,894 shares of Common Stock for issuance under the Plan. The Company’s stock options generally vest on various terms based on continuous services over periods ranging from three The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Before the consummation of the Business Combination, the management of Ambulnz took the average of several publicly traded companies that were representative of Ambulnz’s size and industry in order to estimate its expected stock volatility. Subsequent to the Business Combination, the Company utilized publicly available pricing. The expected term of the options represented the period of time the instruments were expected to be outstanding. The Company based the risk-free interest rate on the rate payable on the U.S. Treasury securities corresponding to the expected term of the awards at the date of grant. Expected dividend yield was zero based on the fact that the Company had not historically paid and does not intend to pay a dividend in the foreseeable future. The following assumptions were used to compute the fair value of the stock option grants during the years ended December 31, 2024 and 2023: Year Ended December 31, 2024 2023 Risk-free interest rate 4.2% - 4.5% 4.1% - 4.9% Expected term (in years) 5.56 6.25 Volatility 61% - 71% 52% - 62% Dividend yield — % — % The following table summarizes the Company’s stock option activity under the Plan for the years ended December 31, 2024 and 2023: Options Weighted Weighted Aggregate Balance as of December 31, 2022 11,571,308 $ 7.11 9.05 $ 39,389,063 Granted/vested during the year 1,566,010 7.93 — — Exercised during the year (514,065) 3.55 — — Cancelled during the year (680,989) 7.52 — — Balance as of December 31, 2023 11,942,264 7.36 8.16 3,961,556 Granted/vested during the year 506,822 3.59 — — Exercised during the year (16,559) 1.59 — — Cancelled during the year (4,265,031) 7.69 — — Balance as of December 31, 2024 8,167,496 6.98 7.32 $ 2,521,202 Options vested and exercisable as of December 31, 2024 4,944,286 $ 6.95 6.82 $ 2,233,701 The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Common Stock price and the exercise price of the stock options. The weighted average grant date fair value per share for stock option grants during the years ended December 31, 2024 and 2023 was $3.59 and $7.93, respectively. On December 31, 2024, 2023 and 2022, the total recorded stock-based compensation related to stock option awards granted was $6,652,789, $11,795,320, and $6,232,992, respectively. On December 31, 2024, 2023 and 2022, the total unrecognized compensation related to unvested stock option awards granted was $11,246,649, $29,058,756 and $41,666,564, respectively, which the Company expects to recognize over a weighted-average period of approximately 1.43 years. Restricted Stock Units The fair value of restricted stock units (“RSUs”) is determined on the date of grant. The Company records compensation expenses in the Consolidated Statements of Operations and Comprehensive Income on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one Activity under RSUs for the year ended December 31, 2024 was as follows: RSUs Weighted- Balance as of December 31, 2023 2,424,095 $ 5.61 Granted 3,009,868 3.94 Vested (1,205,460) 4.82 Forfeited (159,516) 4.92 Balance as of December 31, 2024 4,068,987 4.63 Vested and unissued as of December 31, 2024 10,990 3.42 Non-vested as of December 31, 2024 4,057,997 4.64 The total grant-date fair value of RSUs granted during the year ended December 31, 2024 was $11,854,256. For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense related to RSUs of $5,783,838, $9,101,027, and $1,821,579, respectively, out of which none and $493,043 is included in accrued liabilities as of December 31, 2024 and 2023, respectively. On December 31, 2024, 2023 and 2022, the total unrecognized compensation related to unvested RSUs granted was $17,458,680, $12,602,662 and $2,177,713, respectively, which is expected to be recognized over a weighted-average period of approximately 2.0 years. Performance-based Stock Units The fair value of performance-based stock units (“PSUs”) is determined on the date of grant. The Company records compensation expenses in the Consolidated Statements of Operations and Comprehensive Income on a straight-line basis over the vesting period based on the grant date fair value of the awards and probability of the achievement of the specified performance target. The vesting period for employees and members of the Board of Directors ranges from one Activity under PSUs for the year ended December 31, 2024 was as follows: PSUs Weighted-Average Grant Date Fair Value Per PSU Balance as of December 31, 2023 1,085,270 $ 5.16 Granted 1,205,251 4.19 Vested — — Performance Adjustment (217,054) 5.16 Balance as of December 31, 2024 2,073,467 4.60 Vested and unissued as of December 31, 2024 — — Non-vested as of December 31, 2024 2,073,467 4.60 The total grant-date fair value of PSUs granted during the year ended December 31, 2024 was $9,529,994. For the years ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to PSUs of $1,197,459 and $72,827, respectively, which are included in accrued liabilities. As of December 31, 2024 and 2023, the Company had unrecognized compensation cost related to non-vested PSUs amounting to $8,332,535 and $5,527,166, respectively, which is expected to be recognized over a weighted-average period of approximately 3.0 years.

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases The Company has lease arrangements for properties, vehicles and transportation equipment. Certain leases contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated right-of-use asset and lease obligation. In making such determination, the Company considers all relevant economic factors. The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019 for all leases that commenced prior to that date for office spaces, vehicles and transportation equipment. Lease Costs The table below comprises lease expenses for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease cost: Operating lease expense $ 3,851,686 $ 3,418,134 $ 2,294,636 Finance lease expense: Amortization of right-of-use assets 4,617,262 6,352,754 3,236,418 Interest on lease liabilities 769,041 600,239 559,596 Finance lease expense 5,386,303 6,952,993 3,796,014 Short-term lease expense 2,580,933 1,678,487 1,201,622 Total lease cost $ 11,818,922 $ 12,049,614 $ 7,292,272 Lease Payments The table below comprises lease payments for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease payments: Operating lease payment $ 3,711,545 $ 3,287,125 $ 2,294,636 Finance lease payment 4,334,463 4,270,553 2,985,568 Total lease payments $ 8,046,008 $ 7,557,678 $ 5,280,204 Operating Leases The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space and transportation equipment, expiring at various dates through 2034. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property. Loss (Gain) on Lease Remeasurement During the year, the Company reassessed the use of some office spaces, resulting in the early termination of two leased office spaces. The Company recorded a loss from remeasurement of operating lease of $13,469 and a gain of $4,566 for the years ended December 31, 2024 and 2023, respectively. There were no gains or losses recorded relating to remeasurement of operating leases for the year ended December 31, 2022. Lease Position as of December 31, 2024 and 2023 Right-of-use lease assets and lease liabilities for the Company’s operating leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 11,958,698 $ 9,580,535 Total lease assets $ 11,958,698 $ 9,580,535 Liabilities Current liabilities: Lease liability - current portion $ 3,844,561 $ 2,773,020 Noncurrent liabilities: Lease liability, net of current portion 8,599,072 7,223,941 Total lease liability $ 12,443,633 $ 9,996,961 Lease Terms and Discount Rate Weighted average remaining lease term (in years) - operating leases 3.65 Weighted average discount rate - operating leases 5.86 % Undiscounted Cash Flows Future minimum lease payments under the operating leases as of December 31, 2024 are as follows: Operating 2025 $ 4,475,876 2026 3,832,409 2027 2,585,529 2028 1,763,468 2029 956,779 Thereafter 304,729 Total future minimum lease payments 13,918,790 Less effects of discounting (1,475,157) Present value of future minimum lease payments $ 12,443,633 Finance Leases The Company leases vehicles under non-cancelable finance lease agreements with a liability of $14,725,605, $11,430,465 and $8,646,803 for the years ended December 31, 2024, 2023 and 2022, respectively, and a right-of-use net of $15,337,299, $12,003,919 and $9,039,663 for the years ended December 31, 2024, 2023 and 2022, respectively (accumulated depreciation of $9,128,202, $11,679,823 and $7,906,966 as of December 31, 2024, 2023 and 2022, respectively). Loss (Gain) on Lease Remeasurement During the year, the Company returned a number of leased vehicles, resulting in the termination of contract of these leased vehicles. The Company recorded a loss on remeasurement of finance lease of $18,894 and $5,432 during the years ended December 31, 2024 and 2023 respectively. In June 2022, the Company reassessed its finance lease estimates relating to vehicle mileage and residual value. As a result, the Company determined to purchase the vehicles at the end of the leases, which resulted in a gain of $1.4 million recorded as gain on remeasurement of finance lease on the Consolidated Statements of Operations and Comprehensive Income. Lease Position as of December 31, 2024 and 2023 Right-of-use lease assets and lease liabilities for the Company’s finance leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 15,337,299 $ 12,003,919 Total lease assets $ 15,337,299 $ 12,003,919 Liabilities Current liabilities: Lease liability - current portion $ 4,694,467 $ 3,534,073 Noncurrent liabilities: Lease liability, net of current portion 10,031,138 7,896,392 Total lease liability $ 14,725,605 $ 11,430,465 Lease Terms and Discount Rate The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of December 31, 2024: Weighted average remaining lease term (in years) - finance leases 3.45 Weighted average discount rate - finance leases 5.75 % Undiscounted Cash Flows Future minimum lease payments under the finance leases as of December 31, 2024 are as follows: Finance Leases 2025 $ 5,417,251 2026 4,615,612 2027 3,396,644 2028 2,202,280 2029 660,590 Thereafter — Total future minimum lease payments 16,292,377 Less effects of discounting (1,566,772) Present value of future minimum lease payments $ 14,725,605
Leases	Leases The Company has lease arrangements for properties, vehicles and transportation equipment. Certain leases contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated right-of-use asset and lease obligation. In making such determination, the Company considers all relevant economic factors. The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019 for all leases that commenced prior to that date for office spaces, vehicles and transportation equipment. Lease Costs The table below comprises lease expenses for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease cost: Operating lease expense $ 3,851,686 $ 3,418,134 $ 2,294,636 Finance lease expense: Amortization of right-of-use assets 4,617,262 6,352,754 3,236,418 Interest on lease liabilities 769,041 600,239 559,596 Finance lease expense 5,386,303 6,952,993 3,796,014 Short-term lease expense 2,580,933 1,678,487 1,201,622 Total lease cost $ 11,818,922 $ 12,049,614 $ 7,292,272 Lease Payments The table below comprises lease payments for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease payments: Operating lease payment $ 3,711,545 $ 3,287,125 $ 2,294,636 Finance lease payment 4,334,463 4,270,553 2,985,568 Total lease payments $ 8,046,008 $ 7,557,678 $ 5,280,204 Operating Leases The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space and transportation equipment, expiring at various dates through 2034. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property. Loss (Gain) on Lease Remeasurement During the year, the Company reassessed the use of some office spaces, resulting in the early termination of two leased office spaces. The Company recorded a loss from remeasurement of operating lease of $13,469 and a gain of $4,566 for the years ended December 31, 2024 and 2023, respectively. There were no gains or losses recorded relating to remeasurement of operating leases for the year ended December 31, 2022. Lease Position as of December 31, 2024 and 2023 Right-of-use lease assets and lease liabilities for the Company’s operating leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 11,958,698 $ 9,580,535 Total lease assets $ 11,958,698 $ 9,580,535 Liabilities Current liabilities: Lease liability - current portion $ 3,844,561 $ 2,773,020 Noncurrent liabilities: Lease liability, net of current portion 8,599,072 7,223,941 Total lease liability $ 12,443,633 $ 9,996,961 Lease Terms and Discount Rate Weighted average remaining lease term (in years) - operating leases 3.65 Weighted average discount rate - operating leases 5.86 % Undiscounted Cash Flows Future minimum lease payments under the operating leases as of December 31, 2024 are as follows: Operating 2025 $ 4,475,876 2026 3,832,409 2027 2,585,529 2028 1,763,468 2029 956,779 Thereafter 304,729 Total future minimum lease payments 13,918,790 Less effects of discounting (1,475,157) Present value of future minimum lease payments $ 12,443,633 Finance Leases The Company leases vehicles under non-cancelable finance lease agreements with a liability of $14,725,605, $11,430,465 and $8,646,803 for the years ended December 31, 2024, 2023 and 2022, respectively, and a right-of-use net of $15,337,299, $12,003,919 and $9,039,663 for the years ended December 31, 2024, 2023 and 2022, respectively (accumulated depreciation of $9,128,202, $11,679,823 and $7,906,966 as of December 31, 2024, 2023 and 2022, respectively). Loss (Gain) on Lease Remeasurement During the year, the Company returned a number of leased vehicles, resulting in the termination of contract of these leased vehicles. The Company recorded a loss on remeasurement of finance lease of $18,894 and $5,432 during the years ended December 31, 2024 and 2023 respectively. In June 2022, the Company reassessed its finance lease estimates relating to vehicle mileage and residual value. As a result, the Company determined to purchase the vehicles at the end of the leases, which resulted in a gain of $1.4 million recorded as gain on remeasurement of finance lease on the Consolidated Statements of Operations and Comprehensive Income. Lease Position as of December 31, 2024 and 2023 Right-of-use lease assets and lease liabilities for the Company’s finance leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 15,337,299 $ 12,003,919 Total lease assets $ 15,337,299 $ 12,003,919 Liabilities Current liabilities: Lease liability - current portion $ 4,694,467 $ 3,534,073 Noncurrent liabilities: Lease liability, net of current portion 10,031,138 7,896,392 Total lease liability $ 14,725,605 $ 11,430,465 Lease Terms and Discount Rate The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of December 31, 2024: Weighted average remaining lease term (in years) - finance leases 3.45 Weighted average discount rate - finance leases 5.75 % Undiscounted Cash Flows Future minimum lease payments under the finance leases as of December 31, 2024 are as follows: Finance Leases 2025 $ 5,417,251 2026 4,615,612 2027 3,396,644 2028 2,202,280 2029 660,590 Thereafter — Total future minimum lease payments 16,292,377 Less effects of discounting (1,566,772) Present value of future minimum lease payments $ 14,725,605

Other (Expense) Income

Other (Expense) Income	12 Months Ended
	Dec. 31, 2024
Other Income and Expenses [Abstract]
Other (Expense) Income	Other (Expense) Income The Company recognized $(939,724), $1,238,313 and $950,264 of other (expense) income for the years ended December 31, 2024 , 2023 and 2022, respectively, as set forth in the table below. Year Ended Other (expense) income 2024 2023 2022 Interest (expense) income, net $ (1,929,207) $ 1,684,399 $ 762,685 Gain on remeasurement of warrant liabilities — — 1,127,388 Change in fair value of contingent liability 9,392,133 1,437,525 — Finite-lived intangible asset impairment (8,306,591) — — Goodwill impairment — — (2,921,958) (Loss) gain on equity method investments (316,044) (343,336) 8,919 (Loss) gain on remeasurement of operating and finance leases (32,363) (866) 1,388,273 Gain on bargain purchase — — 1,593,612 Gain (loss) on disposal of fixed assets 23,682 (852,544) (21,173) ABC litigation — (1,000,000) — Other income (expense) 228,666 313,135 (987,482) Total other (expense) income $ (939,724) $ 1,238,313 $ 950,264

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Historically, the Company has been involved in transactions with various related parties. Legal Services Ely D. Tendler is compensated for his services to the Company as General Counsel and Secretary through payments to Ely D. Tendler Strategic & Legal Services PLLC (“EDTSLS”), a law firm owned by Mr. Tendler. All payments made to EDTSLS by the Company were for Mr. Tendler’s services to the Company as General Counsel and Secretary. No other services were provided by EDTSLS to the Company. The Company’s payments to EDTSLS for Mr. Tendler’s services totaled $1,207,843, $916,370 and $960,081 for the years ended December 31, 2024, 2023 and 2022, respectively. Included in accounts payable were $55,545 and $0 due to related parties as of December 31, 2024 and 2023, respectively. There are no amounts related to accrued liabilities as of December 31, 2024 and 2023 related to legal services. Subcontractor Services PrideStaff provides subcontractor services for the Company. PrideStaff is owned by a former operations manager of the Company and his spouse, and therefore, a related party. The Company made subcontractor payments to PrideStaff totaling $155,749, $0 and $547,500 for the years ended December 31, 2024, 2023 and 2022, respectively. Included in accounts payable were $17,149 and $0 due to related parties as of December 31, 2024 and 2023 , respectively. Included in accrued liabilities were $13,097 and $0 due to related parties as of December 31, 2024 and 2023 related to subcontractor services. Transition Services Agr eement On October 11, 2023, the Company and Anthony Capone, who resigned as Chief Executive Officer of the Company on September 15, 2023, entered into a separation and transition services agreement (the “Transition Agreement”). Pursuant to the Transition Agreement, Mr. Capone served as a consultant to the Company until March 15, 2024 (such period, the “Consulting Period”) to advise on matters relating to business continuity and processes and transition his institutional knowledge with respect to operational and other departmental functions. As compensation for his services during the Consulting Period, and subject to his compliance with the Transition Agreement, including the execution and non-revocation of a general release of claims in favor of the Company, Mr. Capone received a monthly consulting fee of $45,000 and subsidized premiums for continued group health plan coverage for the duration of the Consulting Period. Mr. Capone did not receive new equity awards or incentive compensation under the Company’s equity incentive compensation program during the Consulting Period. The Transition Agreement further acknowledges and affirms that Mr. Capone will be bound by and comply with certain restrictive covenants. The Company made payments to Anthony Capone totaling $180,000, $90,000, and $0 for the years ended December 31, 2024, 2023, and 2022 respectively. Included in accounts payable were $0 and $45,000 due to related parties as of December 31, 2024, and 2023, respectively. Consulting Agreement - Stan Vashovsky On March 7, 2024, the Company entered into a separation and consulting agreement (the “Vashovsky Consulting Agreement”) with Stan Vashovsky, who retired as a director and Chair of the Board effective March 31, 2024. Pursuant to the Vashovsky Consulting Agreement, Mr. Vashovsky will continue to serve as a consultant to the Company until March 31, 2025 (such period, the “Vashovsky Consulting Period”). During the Vashovsky Consulting Period, Mr. Vashovsky will provide advisory services as may be requested from time to time by the Company’s executive officers or the Board of Directors and assist with maintaining the Company’s existing customer and investor relationships and, as consideration for his services, receive an equity grant during each quarter of the Vashovsky Consulting Period having a grant date fair value of approximately $35,000. In consideration for a release of claims, Mr. Vashovsky will also be eligible to receive Company-subsidized healthcare coverage for the duration of the Vashovsky Consulting Period. The Vashovsky Consulting Agreement further acknowledges and affirms that Mr. Vashovsky will be bound by and comply with certain restrictive covenants. The Company granted approximately $105,000 in RSUs to Mr. Vashovsky under the Vashovsky Consulting Agreement for the year ended December 31, 2024. There were no amounts included in accounts payable and accrued liabilities as of December 31, 2024 and 2023 related to the Vashovsky Consulting Agreement. Consulting Agreement - Steven Katz On September 26, 2024, the Company entered into a transition consulting agreement (the “Katz Consulting Agreement”) with Steven Katz, who resigned as a director and independent Chair of the Board of Directors effective October 1, 2024. Pursuant to the Katz Consulting Agreement, Mr. Katz served as a consultant to the Company until December 31, 2024 (the “Katz Consulting Period”). During the Katz Consulting Period, Mr. Katz provided transition advisory services relating to the Board and its committees as requested from time to time by the Company’s executive officers or the Board of Directors. As compensation for his services during the Katz Consulting Period, and subject to his compliance with the Katz Consulting Agreement, Mr. Katz received consulting fees in the amount of (i) $2,500 per month plus (ii) $400 for each hour of services rendered in excess of five hours during each month. During the Katz Consulting Period, Mr. Katz’s equity awards also continued to vest under the Plan. The Company made payments to Steven Katz totaling $5,000, $0, and $0 for the years ended December 31, 2024, 2023, and 2022 respectively. Included in accounts payable and accrued liabilities were $2,500 and $0 due to related parties as of December 31, 2024 and 2023, respectively, related to the Katz Consulting Agreement.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate consists of the following: Year Ended 2024 2023 2022 Statutory federal income tax benefit 21.00 % 21.00 % 21.00 % Permanent items 6.33 % 26.18 % 0.56 % State taxes, net of federal tax benefit 19.88 % 20.67 % 7.77 % Rate Change (3.57) % (0.04) % 0.17 % Effects of Rates Different from Statutory (0.35) % 0.04 % 0.01 % Other (9.73) % (29.54) % (3.64) % Change in valuation allowance 18.29 % (1.91) % (54.94) % Income tax provision (benefit) 51.85 % 36.40 % (29.07) % The components of income tax expense (benefit) are as follows: For the Years Ended 2024 2023 2022 Current: Federal $ 6,182,372 $ 2,555,164 $ 1,493,772 State and local 4,739,545 5,782,335 502,872 $ 10,921,917 $ 8,337,499 $ 1,996,644 Deferred: Federal $ 3,250,410 $ 1,650,695 $ (7,683,475) State and local 216,095 (3,256,914) (2,649,791) Foreign — (375,300) 375,301 3,466,505 (1,981,519) (9,957,965) Total income tax expense (benefit) $ 14,388,422 $ 6,355,980 $ (7,961,321) Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows: For the Years Ended 2024 2023 Deferred tax assets: Allowance for credit loss $ 1,519,406 $ 1,683,119 Accrued expenses 901,403 799,295 Lease liability 6,001,016 4,674,177 Stock compensation 5,982,385 5,039,590 Research and development expense 1,399,066 865,800 Net operating loss 8,990,407 4,568,113 Other (375,247) (471,694) Total deferred tax asset $ 24,418,436 $ 17,158,400 Valuation allowance (6,187,664) (1,207,673) Deferred income tax assets, net of allowance $ 18,230,772 $ 15,950,727 Deferred tax liabilities: Prepaid expenses $ (1,007,405) $ (780,767) Depreciation (1,252,332) (3,819,069) Right-of-use asset (5,903,840) (4,544,024) Amortization (1,645,161) 5,081,672 Total deferred tax liability $ (9,808,738) $ (4,062,188) Deferred tax assets, net of allowance $ 8,422,034 $ 11,888,539 The Company has determined, based upon available evidence, that it is more likely than not that all of the net deferred tax asset will not be realized and, accordingly, has provided a partial valuation allowance against its net deferred tax asset as of December 31, 2024 and 2023, respectively. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, net operating loss carryback potential and tax planning strategies in making these assessments. As of December 31, 2024 ,2023 and 2022, the Company had federal net operating loss carryforwards of approximately $0, $0 and $35,289,184, respectively. As of December 31, 2024, 2023, and 2022, the Company had approximately $24,273,354, $10,737,510 and $1,520,345 of foreign net operating loss carryforwards, respectively. As of December 31, 2024, 2023 and 2022, the Company had state net operating loss carryforward of approximately $36,878,259, $36,422,543 and $2,592,560, respectively. The federal net operating loss carryforwards generated after December 31, 2017 of $35,298,184 carry forward indefinitely. State and foreign net operating loss carryforwards generated in the tax years from 2017 to 2020 will begin to expire, if not utilized, by 2040. Utilization of the net operating loss carryforwards may be subject to an annual limitation according to Section 382 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), and similar provisions. The difference between the statutory income taxes on the Company’s pre-tax loss and the Company’s effective income tax rate during the years ended December 31, 2024 and 2023 is primarily due to a recorded valuation allowance and other state taxes. The valuation allowance for deferred tax assets as of December 31, 2024 and 2023 was $6,187,664 and $1,207,673, respectively. The net change in the total valuation allowance for the years ended December 31, 2024, and 2023 was an increase (decrease) of $4,979,991 and $(312,672), respectively. In assessing the realizability of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future table income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued no penalties or interest during the years ended December 31, 2024, 2023, and 2022. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of December 31, 2024, open years related to all jurisdictions are 2023, 2022 and 2021. The Company has an on-going tax audit in California as of December 31, 2024.

401(k) Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
401(k) Plan	401(k) Plan The Company established a 401(k) plan in January 2022 that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. All U.S. employees that complete two months of service with the Company are eligible to participate in the plan. The Company did not make any employer contributions to this plan as of December 31, 2024.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2024
Financial Support for Nonconsolidated Legal Entity [Abstract]
Legal Proceedings	Legal Proceedings From time to time, the Company may be involved as a defendant in legal actions that arise in the normal course of its business. In the opinion of management, the Company has adequate legal defense on all legal actions, and the results of any such proceedings would not materially impact the Consolidated Financial Statements of the Company. The Company provides disclosure and records loss contingencies in accordance with the loss contingencies accounting guidance. In accordance with such guidance, the Company establishes accruals for such matters when potential losses become probable and can be reasonably estimated. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss in its Consolidated Financial Statements. California Labor Actions On March 30, 2023, Paul Lowe v. Rapid Reliable Testing, LLC, et al. was filed in the Los Angeles Superior Court (the “Lowe Action”). The complaint alleges various wage and hour claims on behalf of the plaintiff and a putative class. The complaint also alleges a derivative class claim for violations of California’s Unfair Competition Law and seeks to bring a representative action pursuant to California’s Private Attorneys General Act of 2004 (“PAGA”). In addition, Corielyn Marie Hall v. Rapid Reliable Testing, LLC, et al. involves two separate actions filed in the Los Angeles Superior Court by plaintiff Corielyn Hall (collectively with the Lowe Action, the “California Labor Actions”). The first action is a class complaint filed on December 14, 2023. Similar to the Lowe Action, it alleges various wage and hour claims on behalf of the plaintiff and a putative class and asserts a derivative class claim for violations of California’s Unfair Competition Law. The second action brought by Corielyn Hall was filed on February 20, 2024 and brings claims under PAGA. Given the overlapping claims and time periods presented in the California Labor Actions, in an effort to reach a global resolution, these actions were mediated concurrently on February 5, 2025. The parties reached a resolution, in principle, at the mediation. At the time of this filing, the parties are working to finalize the settlement documents memorializing that resolution. Stockholder Actions On October 27, 2023, Joe Naclerio, individually and purportedly on behalf of all others similarly situated, filed a putative class action complaint for violation of federal securities laws in the U.S. District Court for the Southern District of New York against the Company, its then-Chairman and former Chief Executive Officer, another former Chief Executive Officer, current Chief Financial Officer and former Chief Financial Officer (who currently serves as Executive Vice President of Strategy). On January 17, 2024, the Court appointed the Genesee County Employees’ Retirement System as the Lead Plaintiff. On March 18, 2024, the Lead Plaintiff filed an amended complaint against the Company, its now former Chairman and Chief Executive Officer, another former Chief Executive Officer and former Chief Financial Officer (who currently serves as Executive Vice President of Strategy). On June 21, 2024, the defendants moved to dismiss the amended complaint. The motion was fully briefed in September 2024. Due to the early stage of this proceeding, the Company cannot reasonably estimate the potential range of loss, if any. The Company disputes the allegations of wrongdoing and intends to defend itself vigorously in this matter. On May 30, 2024 and on July 15, 2024, two purported shareholder derivative actions were filed against certain current and former officers and directors of the Company. The Company was named as a nominal defendant in both actions, and the complaints named the Company’s current board of directors, including its Chief Executive Officer and General Counsel, along with two former Chief Executive Officers, the Company’s Chief Financial Officer and Treasurer and its Executive Vice President of Strategy. These actions were filed by Ryne Shetterly in U.S. District Court for the Southern District of New York (the “Shetterly Action”), and Salma Daboul in the Supreme Court for the State of New York (the “Daboul Action”). Both actions purported to assert claims for breach of fiduciary duty and other related claims on behalf of the Company. Both asserted factual allegations substantially similar to those asserted in the securities class action matter discussed above, seeking various forms of monetary and injunctive relief. On August 29, 2024, the U.S. District Court for the Southern District of New York issued an order to transfer the Shetterly Action to the United States District Court for the District of Delaware. On September 6, 2024, the plaintiff in the Daboul Action voluntarily discontinued the action. On November 25, 2024, the parties filed a stipulation and proposed order for voluntary dismissal of the Shetterly Action, which the judge signed. Cybersecurity Action

Risk and Uncertainties

Risk and Uncertainties	12 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
Risk and Uncertainties	Risk and Uncertainties Risks, Impacts and Uncertainties The Company’s current business plan assumes increased demand for Mobile Health Services. Demand for such services was accelerated by the pandemic, but is also being driven by longer-term secular factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s offices and hospitals. Government Contracts In recent years, the Company’s government contract work has represented a substantial portion of its overall revenue, and maintaining and continuing to grow this revenues stream is an important part of the Company’s growth strategy. However, government contract work is subject to risks and uncertainties. Government contract work subjects the Company to government audits, investigations and proceedings, which could also lead to the Company to being barred from government work or subjected to fines if it is determined that a statute, rule, regulation, policy or contractual provision has

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of Professional Technicians, Inc. On February 10, 2025, Holdings acquired 100% of the outstanding shares of common stock of Professional Technicians, Inc. (“PTI”). The aggregate purchase price consisted of $4,000,000 in cash consideration, $3,800,000 of which was paid at closing. The Company also agreed to pay PTI up to an additional $1,500,000 in deferred consideration upon meeting certain performance conditions through the period beginning on April 1, 2025 and ending on March 31, 2026.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	In the ordinary course of our business, we collect, use, store and transmit digitally large amounts of confidential, sensitive, proprietary, personal and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy, and we consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. To this end, we have implemented processes designed to assess, identify and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated information technology team, led by our Chief Information Security Officer (“CISO”), who also serves as our Chief Information Officer, and include mechanisms, controls, technologies, systems and other processes designed to prevent or mitigate data loss, theft, misuse or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, data recovery testing, security audits and ongoing risk assessments, including due diligence on and audits of our key technology vendors and other contractors and suppliers. We also conduct regular employee trainings on cyber and information security, among other topics. In addition, we consult with outside advisors and experts, when appropriate, to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends and their impact on the Company’s risk environment. We also rely on information technology and third party vendors to support our operations, including our secure processing of personal, confidential, sensitive, proprietary and other types of information. With respect to incident response, we have adopted a Cybersecurity Incident Response Plan that applies in the event of a cybersecurity threat or incident (the “IRP”) to provide a standardized framework for responding to security incidents. The IRP sets out a coordinated approach to investigating, containing, documenting and mitigating incidents, including reporting findings and keeping senior management and other key stakeholders informed and involved as appropriate. In general, our incident response process follows the National Institute of Standards and Technology framework and focuses on four phases: • preparation and prevention; • detection and analysis; • containment, eradication and recovery; and • post-incident remediation. The IRP applies to all Company personnel (including third-party contractors, vendors and partners) that perform functions or services that require access to secure Company information, and to all devices and network services that are owned or managed by the Company. Despite ongoing efforts to continually improve our and our vendors’ ability to protect against cyber incidents, we may not be able to protect all information systems, and such incidents may lead to reputational harm, revenue and client loss, legal actions and statutory penalties, among other consequences. Based on the information available as of the date of this Annual Report, we believe that risks from cybersecurity threats, including as a result of previous cybersecurity incidents, have not materially affected us, including our business strategy, results of operations or financial condition, and as of the date of this Annual Report, the Company is not aware of any material risks from cybersecurity threats that are reasonably likely to do so. However, there can be no guarantee that we will not be the subject of future cybersecurity attacks, threats or incidents that may materially affect our business strategy, results of operations or financial condition. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, “Risk Factors,” under the heading “Risks Related to Information Technology.”
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	The secure maintenance of this information and our information technology systems is important to our operations and business strategy, and we consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. To this end, we have implemented processes designed to assess, identify and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity and availability of these systems and the data residing therein.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Board’s Audit and Compliance Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit and Compliance Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our CISO, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The Board also receives updates from management and the Audit and Compliance Committee on cybersecurity risks on at least an annual basis. In addition, we have protocols by which certain cybersecurity incidents are escalated within the Company and, where appropriate, reported promptly to the Board and Audit and Compliance Committee.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Board’s Audit and Compliance Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit and Compliance Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our CISO, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties.
Cybersecurity Risk Role of Management [Text Block]	Our CISO, who reports to our Chief Financial Officer, is responsible for assessing and managing cybersecurity risks. Our CISO has over 20 years of experience in cybersecurity, risk management and information security governance and holds Certified Information Systems Security Professional (CISSP) and Certified Information Security Manager (CISM) certifications. Our CISO receives reports on cybersecurity threats from our dedicated information technology team on an ongoing basis and, in conjunction with management, regularly review risk management measures implemented by the Company to identify and mitigate data protection and cybersecurity risks. Our CISO also works closely with our legal and compliance departments to oversee compliance with legal, regulatory and contractual security requirements.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our CISO, who reports to our Chief Financial Officer, is responsible for assessing and managing cybersecurity risks. Our CISO has over 20 years of experience in cybersecurity, risk management and information security governance and holds Certified Information Systems Security Professional (CISSP) and Certified Information Security Manager (CISM) certifications. Our CISO receives reports on cybersecurity threats from our dedicated information technology team on an ongoing basis and, in conjunction with management, regularly review risk management measures implemented by the Company to identify and mitigate data protection and cybersecurity risks. Our CISO also works closely with our legal and compliance departments to oversee compliance with legal, regulatory and contractual security requirements. The Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage and mitigate those risks. The Board’s Audit and Compliance Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit and Compliance Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our CISO, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The Board also receives updates from management and the Audit and Compliance Committee on cybersecurity risks on at least an annual basis. In addition, we have protocols by which certain cybersecurity incidents are escalated within the Company and, where appropriate, reported promptly to the Board and Audit and Compliance Committee.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CISO has over 20 years of experience in cybersecurity, risk management and information security governance and holds Certified Information Systems Security Professional (CISSP) and Certified Information Security Manager (CISM) certifications.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our CISO receives reports on cybersecurity threats from our dedicated information technology team on an ongoing basis and, in conjunction with management, regularly review risk management measures implemented by the Company to identify and mitigate data protection and cybersecurity risks. Our CISO also works closely with our legal and compliance departments to oversee compliance with legal, regulatory and contractual security requirements.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts and operations of DocGo Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI“) on the Consolidated Financial Statements represent a portion of consolidated joint ventures and variable interest entities (“VIEs“) in which the Company does not have direct equity ownership. Certain amounts in the prior years’ Consolidated Statements of Changes in Stockholders’ Equity and Consolidated Statements of Cash Flows have been reclassified to conform to the current year presentation. In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are VIEs. For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. The Company has entered into management services agreements (“MSAs”) with professional corporations (“PCs”) that employ or contract with physicians and other health professionals in order to provide healthcare services to the public. Each such PC is established and operated pursuant to the requirements of its respective domestic jurisdiction governing the practice of medicine. The Company provides each PC with everything the PC needs to operate except for clinicians, which the PC is responsible for. Without the administrative services, software, intellectual property and administrative personnel (among other things) provided by the Company, the PCs could not carry out their businesses. Moreover, the PCs do not have sufficient equity to finance their activities without additional subordinated financial support. Based on the foregoing, these entities are considered VIEs, and an enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is the primary beneficiary, meaning it has (1) the power to direct the activities of the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). In accordance with corporate practice of medicine restrictions, all clinical treatment decisions are made solely by licensed healthcare professionals engaged by the PCs. Nevertheless, the PCs cannot operate without the Company through the MSAs; therefore the Company significantly impacts the economic performance of the PCs and funds and absorbs all losses of its VIEs. The Company has therefore determined that it is the primary economic beneficiary of the PCs and appropriately consolidates them as VIEs.
Foreign Currency	Foreign Currency The Company’s functional currency is the U.S. dollar. The functional currency of our foreign operation is the British pound. Assets and liabilities of the Company’s foreign operation denominated in the British pound are translated at the spot rate in effect at the applicable reporting date, except for equity accounts which are translated at historical rates. The Consolidated Statements of Operations and Comprehensive Income are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment for the years ended December 31, 2024, 2023 and 2022 were $(263,036), $743,699, and $773,707, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses; the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition related to the allowance for credit loss, stock-based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, contingent consideration, reserve for losses within the Company’s insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations could be adversely affected.
Self Insurance Reserves	Self-Insurance Reserves The Company self-insures a number of risks, including, but not limited to, workers’ compensation, general liability, auto liability and certain employee-related healthcare benefits. Standard actuarial procedures and data analysis are used to estimate the liabilities associated with these risks on an undiscounted basis. The recorded liabilities reflect the ultimate cost for claims incurred but not paid and any estimable administrative run-out expenses related to the processing of these outstanding claim payments. On a regular basis, the liabilities are evaluated for appropriateness with claims reserve valuations. To limit exposure to some risks, the Company maintains insurance coverage with varying limits and retentions, including stop-loss insurance coverage for workers’ compensation, general liability and auto liability.
Concentration of Credit Risk and Off-Balance Sheet Risk	Concentration of Credit Risk and Off-Balance Sheet Risk The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.
Reclassifications	Reclassifications Certain reclassifications of amounts previously reported have been made to the accompanying Consolidated Financial Statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net income or retained earnings.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the U.S. The Company’s accounts at financial institutions in the U.S. are insured by the FDIC and are in excess of FDIC insured limits.
Restricted Cash	Restricted Cash Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for self-insurance exposures, and a standby letter of credit as required by its insurance carrier (see Note 10). The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits. ARM Insurance, Inc., a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820, Fair Value Measurements , provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2024, December 31, 2023 and December 31, 2022. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses, and due to seller, the carrying amounts approximate their fair values as it is short term in nature. The notes payable are presented at their carrying value, which, based on borrowing rates currently available to the Company for loans with similar terms, approximates its fair values.
Impairment of Finite-Lived Intangible Assets	Impairment of Finite-Lived Intangible Assets
Equity Investment Without Readily Determinable Fair Value	Equity Investment Without Readily Determinable Fair Value The Company has invested in equity securities without readily determinable fair values and has elected to measure them using the measurement alternative in accordance with ASC 321, Investments - Equity Securities (“ASC 321”). This investment is carried at cost less any impairment and adjusted to fair value if there are observable price changes for an identical or similar investment of the same issuer. Refer to Note 8. Equity Investment without Readily Determinable Fair Value Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the Company) which do not have readily determinable fair values are recorded as equity investments without readily determinable fair value in accordance with ASC 321. All equity investments without readily determinable fair value are assessed for impairment when events or changes in circumstances indicate that the carrying amounts may not be recoverable, and measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The recoverable value of the investment was determined based on the Company’s best estimate of the amount that could be realized from the investment, which considered the latest financial information. During the years ended December 31, 2024, 2023 and 2022, no impairment losses were recognized for the equity investments without readily determinable fair values.
Accounts Receivable	Accounts Receivable The Company contracts with hospitals, healthcare facilities, businesses, state and local government entities, and insurance providers to provide Mobile Health Services and Transportation Services at specified rates. These rates are either on a per procedure or per transport basis, or on an hourly or daily basis. Accounts receivable consist of billings for healthcare and transportation services provided to patients. Billings typically are either paid or settled on the patient’s behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs or businesses or patients directly. The Company generally does not require collateral for accounts receivable . Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time of billing based on contractual terms or other arrangements. The Company maintains an allowance for credit losses for accounts receivable, net which is recorded as an offset to accounts receivable, net and changes in this allowance are recorded within general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Income (Loss). The carrying amount of accounts receivable represents the maximum credit risk exposure of these assets. On a quarterly basis, in accordance with Federal Accounting Standards Board (“FASB”) ASC 326, Measurement of Credit Losses on Financial Instruments , the Company evaluates the collectability of outstanding accounts receivable balances to determine an allowance for credit loss that reflects its best estimate of the lifetime expected credit losses. Individual uncollectible accounts are written off against the allowance when collection of the individual account does not appear probable. Under the current expected credit loss impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on a single portfolio segment. The Company assesses collectability by aggregating and reviewing accounts receivable on a collective basis for customers that share similar risk characteristics. Additionally, when accounts receivable do not share risk characteristics with other accounts receivables, management will evaluate such accounts receivable for expected credit loss on an individual specific identification basis when the Company identifies specific customers with known disputes or collectability issues. Due to the short-term nature of the Company’s accounts receivables, the estimate of expected credit loss is based on the aging of accounts using an aging schedule as of period ends. In determining the amount of the allowance for credit losses, the Company considers historical collection history based on past due status, the current aging of receivables, customer-specific credit risk factors including their current financial condition, current market conditions, and probable future economic conditions which inform adjustments to historical loss patterns. As of January 1, 2024, the Company held a beginning balance in its allowance for credit losses on accounts receivable of $6,276,454. The Company recognized an additional provision for credit losses of $4,384,866 and write offs of $(4,787,379) during the year. The Company’s balance in its allowance for credit losses amounted to $5,873,942 as of December 31, 2024 .
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the Consolidated Statements of Operations and Comprehensive Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows: Estimated Useful Life Buildings 39 years Office equipment and furniture 3-7 years Vehicles 5-8 years Medical equipment 5 years Leasehold improvements Shorter of useful life of asset or lease term Expenditures for repairs and maintenance are charged to expense as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.
Software Development Costs	Software Development Costs Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software . Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life. Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.
Business Combinations	Business Combinations The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations. The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
Goodwill and Indefinite-Lived Intangible Assets	Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization, as indicated by its publicly quoted share price, below its net book value.
Line of Credit	Line of Credit The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense. Interest expense on outstanding balances is expensed as incurred.
Derivative Liabilities	Derivative Liabilities
Related Party Transactions	Related Party Transactions The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, members of immediate families of principal owners or management, and other parties with which the Company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Related party transactions are recorded within operating expenses in the Consolidated Statements of Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the years ended December 31, 2024, 2023 and 2022 refer to Note 18.
Revenue Recognition	Revenue Recognition On January 1, 2019, the Company adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”). To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer. The Company generates revenues from the provision of (1) Mobile Health Services and (2) Transportation Services. Since the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. The transaction price associated with the Company’s contracts with customers is generally determined based on fixed and determinable amounts of consideration as specified in a contract, which includes a fixed base rate and/or fixed mileage rate. For Transportation Services arrangements with billings to third party payors and healthcare facilities, this may also include variable consideration in instances where it is considered probable that a significant reversal of cumulative revenue recognized will not occur. For these services, revenues are recorded net of estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowance at the time of billing based on contractual terms, historical collections or other arrangements. The Company also estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company utilizes the expected value method when estimating its variable consideration. The assumptions utilized in estimating variable consideration include the Company’s previous experience with similar contracts and history of collection rates on prior trips that have been performed. The Company reevaluates its variable consideration at each reporting period. Nature of the Company’s Services Revenue is primarily derived from: i. Mobile Health Services : These services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter. ii. Transportation Services : These services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities. For Mobile Health Services, the performance of the services and any related support activities in the majority of the Company’s contracts are a single performance obligation under ASC 606. Mobile Health Services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized. The Company concluded that Transportation Services and any related support activities are a single performance obligation under ASC 606. As the performance associated with such services is known and quantifiable at the end of a period in which the services occurred (i.e., monthly or quarterly), revenues are typically recognized in the respective period performed. The typical billing cycle for Mobile Health Services and Transportation Services is same day to five days with payments generally due within 30 days. For large municipal customers in the Mobile Health Services segment, invoices are generally produced on a monthly basis, in arrears, and are generally due within 30-60 days of when they are submitted to the customer. The majority of the Company’s Mobile Health Services and Transportation Services each represent a single performance obligation. Therefore, allocation is not necessary as the transaction price (fees) for the services provided is standard and explicitly stated in the contractual fee schedule and/or invoice. For contracts with multiple distinct performance obligations, the Company allocates the transaction price based on their agreed-upon price to the individually identified performance obligations in the contract. The Company monitors and evaluates all contracts on a case-by-case basis to determine if multiple performance obligations are present in a contractual arrangement.
Stock Based Compensation	Stock Based Compensation The Company maintains stock incentive plans under which the Company may issue incentive and non-qualified stock options, restricted stock units and performance-based stock units. The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation , which requires the recognition of the fair value of stock-based compensation. The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company accounts for forfeitures as they occur. For performance-based awards, expense is recognized over the period from the grant date to the estimated attainment date, which is the derived service period of the award, if the management determines that it is probable that the performance-based vesting conditions will be achieved. All stock-based compensation costs are recorded in operating expenses in the Consolidated Statements of Operations and Comprehensive Income.
Earnings per Share	Earnings per Share Earnings per share represents the net income attributable to stockholders divided by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock during the reporting periods. Potential dilutive Common Stock equivalents consist of the incremental shares of Common Stock issuable upon conversion of stock options, unvested RSUs and PSUs. In reporting periods in which the Company has a net loss, the effect is considered anti-dilutive and excluded from the diluted earnings per share calculation.
Equity Method Investment	Equity Method Investment The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s judgment regarding its level of influence over an equity method investee includes considering key factors, such as ownership interest, representation on the board of directors and participation in policy-making decisions. Under the equity method, the Company’s investment is initially measured at cost and subsequently increased or decreased to recognize the Company’s share of income and losses of the investee, capital contributions and distributions and impairment losses. The Company periodically reviews the investments for other than temporary declines in fair value below cost or more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.
Leases	Leases The Company categorizes leases at its inception as either operating or finance leases based on the criteria in ASC 842, Leases (“ASC 842”). The Company adopted ASC 842 on January 1, 2019, using the modified retrospective approach, and has established a right-of-use asset and a current and non-current lease liability for each lease arrangement identified. The lease liability is recorded at the present value of future lease payments discounted using the discount rate that approximates the Company’s incremental borrowing rate for the lease established at the commencement date, and the right-of-use asset is measured as the lease liability plus any initial direct costs, less any lease incentives received before commencement. The Company recognizes a single lease cost, so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis. The Company has lease arrangements for vehicles, equipment and facilities. These leases typically have original terms not exceeding 10 years and in some cases contain multi-year renewal options, none of which are reasonably certain of exercise. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there are such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as short-term leases.
Income Taxes	Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Recently Issued Accounting Standards Adopted and Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure (“ASU 2023-07”). ASU 2023-07 updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The Company adopted ASU 2023-07 in the fourth quarter of 2024. Adoption of this standard modified the Company’s segment disclosures but did not have a material impact on the Company’s Consolidated Balance Sheets, Consolidated Statements of Operations and Comprehensive Income, or Consolidated Statements of Cash Flows. Refer to Note 13 for the updated presentation. Recently Issued Accounting Standards Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting ASU 2023-09 on its disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets	A summary of estimated useful lives is as follows: Estimated Useful Life Buildings 39 years Office equipment and furniture 3-7 years Vehicles 5-8 years Medical equipment 5 years Leasehold improvements Shorter of useful life of asset or lease term
Schedule of revenue is disaggregated	In the following table, revenue is disaggregated as follows: Revenue Breakdown Year ended December 31, 2024 2023 2022 Primary Geographical Markets U.S. $ 558,790,845 $ 571,887,943 $ 419,578,082 U.K. 57,764,287 52,400,699 20,937,664 Total revenue $ 616,555,132 $ 624,288,642 $ 440,515,746 Major Segments/Service Lines Mobile Health Services $ 423,126,040 $ 442,793,537 $ 325,891,440 Transportation Services 193,429,092 181,495,105 114,624,306 Total revenue $ 616,555,132 $ 624,288,642 $ 440,515,746
Schedule of basic and diluted net income per share	Year Ended December 31, 2024 2023 2022 Net income attributable to stockholders of DocGo Inc. and Subsidiaries $ 19,992,143 $ 6,858,455 $ 34,584,498 Weighted-average shares - basic 102,395,141 103,511,299 101,228,369 Effect of dilutive options 7,027,699 2,106,518 1,747,462 Weighted-average shares - dilutive 109,422,840 105,617,817 102,975,831 Net income per share attributable to DocGo Inc. and Subsidiaries - Basic 0.20 0.07 0.34 Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted 0.18 0.06 0.34 Anti-dilutive employee share-based awards excluded 7,251,625 10,638,371 9,000,750

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	Property and equipment, net as of December 31, 2024 and 2023 are as follows: December 31, December 31, Transportation equipment $ 17,300,595 $ 17,438,072 Medical equipment 9,210,203 7,104,161 Office equipment and furniture 4,293,100 3,701,657 Leasehold improvements 1,239,089 709,619 Buildings 527,283 527,283 Land 37,800 37,800 32,608,070 29,518,592 Less: Accumulated depreciation (17,726,659) (12,683,108) Property and equipment, net $ 14,881,411 $ 16,835,484

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of preliminary allocation of assets acquired and liabilities assumed	The following table presents the assets acquired and liabilities assumed at the date of the acquisitions: Ambulnz CO FMC NA CRMS Total Consideration: Cash consideration $ 1,848,000 $ 4,000,000 $ 9,000,000 $ 14,848,000 Stock consideration — 3,000,000 1,000,000 4,000,000 Due to seller — — — — Amounts held under an escrow account — — — — Contingent liability — — 15,822,190 15,822,190 Total consideration $ 1,848,000 $ 7,000,000 $ 25,822,190 $ 34,670,190 Recognized amounts of identifiable assets acquired and liabilities assumed Cash $ — $ — $ 1,574,604 $ 1,574,604 Accounts receivable — — 2,033,533 2,033,533 Other current assets — — 293,478 293,478 Property and equipment — — — — Intangible assets — — 15,930,000 15,930,000 Total identifiable assets acquired — — 19,831,615 19,831,615 Accounts payable — — 28,978 28,978 Due to seller — — 2,448,460 2,448,460 Other current liabilities — — 174,177 174,177 Total liabilities assumed — — 2,651,615 2,651,615 Noncontrolling interests 2,188,450 2,567,037 — 4,755,487 Goodwill — — 8,642,190 8,642,190 Additional paid-in-capital (340,450) 4,432,963 — 4,092,513 Total purchase price $ 1,848,000 $ 7,000,000 $ 25,822,190 $ 34,670,190
Schedule of pro forma combined financial information	The following unaudited pro forma combined financial information for the fiscal years ended December 31, 2023 and 2022 gives effect to the acquisitions disclosed above as if they had occurred on January 1, 2022. The pro forma information is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. The figures presented below for the year ended December 31, 2023 represent the actual results of the Company, as the financial results of CRMS were consolidated in the Company’s results of operations for the entirety of the period. 2023 2022 Revenue $ 627,402,261 $ 539,522,587 Net income $ 11,087,122 $ 46,960,359

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying value of goodwill	The changes in the carrying value of goodwill for the year ended December 31, 2024 are as noted in the table below: Carrying Value Balance as of December 31, 2022 $ 38,900,413 Goodwill acquired during the period 8,642,190 Currency translation adjustment and others (2,674) Balance as of December 31, 2023 $ 47,539,929 Currency translation adjustment and others (107,379) Balance as of December 31, 2024 $ 47,432,550

Intangibles (Tables)

Intangibles (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets consisted of the following as of December 31, 2024 and 2023: December 31, 2024 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (242,059) $ 5,769 Operating licenses Indefinite 9,399,004 — — — 9,399,004 Internally developed software 4-5 years 10,078,087 2,051,826 — (11,227,960) 901,953 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 28,337,524 (37,400) (8,306,591) (6,504,390) 13,489,143 Trademark 8-15 years 427,531 (21,999) — (100,138) 305,394 Non-compete agreements 5 years 100,000 — — (35,000) 65,000 Trade credits 5 years 1,500,000 — — — 1,500,000 $ 50,152,524 $ 1,992,427 $ (8,306,591) $ (18,109,547) $ 25,728,813 December 31, 2023 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (235,967) $ 11,861 Operating licenses Indefinite 8,799,004 600,000 — — 9,399,004 Internally developed software 4-5 years 8,284,058 1,794,029 — (8,821,563) 1,256,524 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 12,397,954 15,939,570 — (3,334,925) 25,002,599 Trademark 8-15 years 389,469 38,062 — (62,141) 365,390 Non-compete agreements 5 years — 100,000 — (15,000) 85,000 Trade credits 5 years — 1,500,000 — — 1,500,000 $ 30,180,863 $ 19,971,661 $ — $ (12,469,596) $ 37,682,928
Schedule of Indefinite-Lived Intangible Assets	Intangible assets consisted of the following as of December 31, 2024 and 2023: December 31, 2024 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (242,059) $ 5,769 Operating licenses Indefinite 9,399,004 — — — 9,399,004 Internally developed software 4-5 years 10,078,087 2,051,826 — (11,227,960) 901,953 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 28,337,524 (37,400) (8,306,591) (6,504,390) 13,489,143 Trademark 8-15 years 427,531 (21,999) — (100,138) 305,394 Non-compete agreements 5 years 100,000 — — (35,000) 65,000 Trade credits 5 years 1,500,000 — — — 1,500,000 $ 50,152,524 $ 1,992,427 $ (8,306,591) $ (18,109,547) $ 25,728,813 December 31, 2023 Estimated Useful Gross Carrying Additions Impairment Accumulated Net Carrying Computer software 5 years $ 247,828 $ — $ — $ (235,967) $ 11,861 Operating licenses Indefinite 8,799,004 600,000 — — 9,399,004 Internally developed software 4-5 years 8,284,058 1,794,029 — (8,821,563) 1,256,524 Material contracts Indefinite 62,550 — — — 62,550 Customer relationships 8-9 years 12,397,954 15,939,570 — (3,334,925) 25,002,599 Trademark 8-15 years 389,469 38,062 — (62,141) 365,390 Non-compete agreements 5 years — 100,000 — (15,000) 85,000 Trade credits 5 years — 1,500,000 — — 1,500,000 $ 30,180,863 $ 19,971,661 $ — $ (12,469,596) $ 37,682,928
Schedule of amortization expense for the next five years in aggregate	Future amortization expense at December 31, 2024 for the next five years and in the aggregate are as follows: Amortization 2025 $ 2,839,672 2026 2,167,093 2027 2,149,822 2028 2,113,652 2029 2,080,148 Thereafter 3,416,872 Total $ 14,767,259

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Carrying Amount of Investments	The Company’s ownership interest and carrying amounts of investments as of December 31, 2024 and 2023 consist of the following: December 31, December 31, Percentage Ownership Amount Percentage Ownership Amount Equity investment without readily determinable fair value $ 5,000,000 $ — Equity method investment Various 547,979 Various 553,573 Total investments $ 5,547,979 $ 553,573

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	Accrued liabilities consisted of the following at the dates indicated: December 31, December 31, Accrued workers' compensation and other insurance liabilities $ 16,738,835 $ 12,881,902 Accrued general expenses 13,924,809 27,001,232 Accrued subcontractors 9,174,499 37,858,755 Accrued payroll 4,374,654 6,464,192 Accrued bonus 3,078,445 4,784,005 Other current liabilities 2,605,554 2,350,523 Total accrued liabilities $ 49,896,796 $ 91,340,609

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of notes payable	The following table summarizes the Company’s notes payable: December 31, December 31, Equipment and financing loans payable, between 2.5% and 4.8% interest and maturing on May 2026 and August 2026 $ 17,730 $ 69,717 Total notes payable 17,730 69,717 Less: current portion of notes payable 12,515 28,131 Total non-current portion of notes payable $ 5,215 $ 41,586
Schedule of future minimum annual maturities of notes payable	Future minimum annual maturities of notes payable as of December 31, 2024 are as follows: Notes Payable 2025 $ 12,515 2026 5,215 Total maturities 17,730 Current portion of notes payable (12,515) Long-term portion of notes payable $ 5,215

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of operating results for the business segments	Operating results for the business segments of the Company are as follows: Mobile Health Transportation Corporate Total Year Ended December 31, 2024 Revenues $ 423,126,040 $ 193,429,092 $ — $ 616,555,132 Significant Segment Expenses 248,887,401 157,386,875 38,938,940 445,213,216 Personnel costs 115,480,700 120,548,486 34,009,595 270,038,781 Subcontractor costs 125,495,305 19,463,199 4,929,345 149,887,849 Vehicle costs 7,911,396 17,375,190 — 25,286,586 Other segment items 80,212,789 38,087,398 24,353,003 142,653,190 Income (loss) from operations 94,025,850 (2,045,181) (63,291,943) 28,688,726 Depreciation and amortization expense 4,770,367 8,305,049 2,809,482 15,884,898 Stock compensation 6,033,516 274,207 7,326,363 13,634,086 Finite-lived intangible asset impairment 8,306,591 — — 8,306,591 Change in fair value of contingent consideration (9,392,133) — — (9,392,133) Total assets 208,739,901 134,169,086 112,712,145 455,621,132 Long-lived assets 36,515,356 68,846,225 9,977,190 115,338,771 Capital expenditures 2,815,218 9,324,171 2,179,585 14,318,974 Year Ended December 31, 2023 Revenues $ 442,793,537 $ 181,495,105 $ — $ 624,288,642 Significant Segment Expenses 283,980,203 146,950,131 44,139,528 475,069,862 Personnel costs 122,233,677 116,689,011 40,156,572 279,079,260 Subcontractor costs 155,134,128 15,380,523 3,982,956 174,497,607 Vehicle costs 6,612,398 14,880,597 — 21,492,995 Other segment items 78,450,514 31,003,597 24,709,689 134,163,800 Income (loss) from operations 80,362,820 3,541,377 (68,849,217) 15,054,980 Depreciation and amortization expense 4,226,657 9,393,895 2,811,340 16,431,892 Stock compensation 1,698,350 1,434,505 17,836,319 20,969,174 Finite-lived intangible asset impairment — — — — Change in fair value of contingent consideration (1,437,525) — — (1,437,525) Total assets 280,646,925 132,178,214 77,626,818 490,451,957 Long-lived assets 32,841,680 78,848,587 11,952,528 123,642,795 Capital expenditures 30,163,882 20,254,373 597,283 51,015,538 Year Ended December 31, 2022 Revenues $ 325,891,440 $ 114,624,306 $ — $ 440,515,746 Significant Segment Expenses 189,978,467 102,697,543 33,409,491 326,085,501 Personnel costs 95,636,747 81,851,310 31,055,130 208,543,187 Subcontractor costs 83,158,899 8,236,644 2,354,361 93,749,904 Vehicle costs 11,182,821 12,609,589 — 23,792,410 Other segment items 43,202,810 26,472,934 22,922,873 92,598,617 Income (loss) from operations 92,710,163 (14,546,171) (56,332,364) 21,831,628 Depreciation and amortization expense 1,685,114 6,050,265 2,830,199 10,565,578 Stock compensation 1,425,299 1,415,670 5,213,602 8,054,571 Finite-lived intangible asset impairment — — — — Change in fair value of contingent consideration — — — — Total assets 116,821,500 118,627,613 157,828,515 393,277,628 Long-lived assets 33,181,594 65,580,291 2,479,889 101,241,774 Capital expenditures 39,569,802 52,105,196 2,542,854 94,217,852
Long-Lived Assets by Geographic Areas	The following table summarizes Long-lived assets by geographic location for the years ended December 31, 2024, 2023, and 2022: December 31, 2024 2023 2022 Primary Geographical Markets U.S. $ 96,380,597 $ 103,779,506 $ 83,145,362 U.K. 18,958,174 19,863,289 18,096,412 Total long-lived assets $ 115,338,771 $ 123,642,795 $ 101,241,774

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of fair value of the sole stock option grants	The following assumptions were used to compute the fair value of the stock option grants during the years ended December 31, 2024 and 2023: Year Ended December 31, 2024 2023 Risk-free interest rate 4.2% - 4.5% 4.1% - 4.9% Expected term (in years) 5.56 6.25 Volatility 61% - 71% 52% - 62% Dividend yield — % — %
Schedule of company’s stock option activity	The following table summarizes the Company’s stock option activity under the Plan for the years ended December 31, 2024 and 2023: Options Weighted Weighted Aggregate Balance as of December 31, 2022 11,571,308 $ 7.11 9.05 $ 39,389,063 Granted/vested during the year 1,566,010 7.93 — — Exercised during the year (514,065) 3.55 — — Cancelled during the year (680,989) 7.52 — — Balance as of December 31, 2023 11,942,264 7.36 8.16 3,961,556 Granted/vested during the year 506,822 3.59 — — Exercised during the year (16,559) 1.59 — — Cancelled during the year (4,265,031) 7.69 — — Balance as of December 31, 2024 8,167,496 6.98 7.32 $ 2,521,202 Options vested and exercisable as of December 31, 2024 4,944,286 $ 6.95 6.82 $ 2,233,701
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity	Activity under RSUs for the year ended December 31, 2024 was as follows: RSUs Weighted- Balance as of December 31, 2023 2,424,095 $ 5.61 Granted 3,009,868 3.94 Vested (1,205,460) 4.82 Forfeited (159,516) 4.92 Balance as of December 31, 2024 4,068,987 4.63 Vested and unissued as of December 31, 2024 10,990 3.42 Non-vested as of December 31, 2024 4,057,997 4.64
Share-Based Payment Arrangement, Performance Shares, Activity	Activity under PSUs for the year ended December 31, 2024 was as follows: PSUs Weighted-Average Grant Date Fair Value Per PSU Balance as of December 31, 2023 1,085,270 $ 5.16 Granted 1,205,251 4.19 Vested — — Performance Adjustment (217,054) 5.16 Balance as of December 31, 2024 2,073,467 4.60 Vested and unissued as of December 31, 2024 — — Non-vested as of December 31, 2024 2,073,467 4.60

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lease Costs	The table below comprises lease expenses for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease cost: Operating lease expense $ 3,851,686 $ 3,418,134 $ 2,294,636 Finance lease expense: Amortization of right-of-use assets 4,617,262 6,352,754 3,236,418 Interest on lease liabilities 769,041 600,239 559,596 Finance lease expense 5,386,303 6,952,993 3,796,014 Short-term lease expense 2,580,933 1,678,487 1,201,622 Total lease cost $ 11,818,922 $ 12,049,614 $ 7,292,272 The table below comprises lease payments for the years ended December 31, 2024, 2023 and 2022, respectively: December 31, 2024 2023 2022 Components of total lease payments: Operating lease payment $ 3,711,545 $ 3,287,125 $ 2,294,636 Finance lease payment 4,334,463 4,270,553 2,985,568 Total lease payments $ 8,046,008 $ 7,557,678 $ 5,280,204
Assets And Liabilities, Lessee	Right-of-use lease assets and lease liabilities for the Company’s operating leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 11,958,698 $ 9,580,535 Total lease assets $ 11,958,698 $ 9,580,535 Liabilities Current liabilities: Lease liability - current portion $ 3,844,561 $ 2,773,020 Noncurrent liabilities: Lease liability, net of current portion 8,599,072 7,223,941 Total lease liability $ 12,443,633 $ 9,996,961 Lease Terms and Discount Rate Weighted average remaining lease term (in years) - operating leases 3.65 Weighted average discount rate - operating leases 5.86 % Right-of-use lease assets and lease liabilities for the Company’s finance leases were recorded in the Consolidated Balance Sheets as follows: December 31, 2024 2023 Assets Lease right-of-use assets $ 15,337,299 $ 12,003,919 Total lease assets $ 15,337,299 $ 12,003,919 Liabilities Current liabilities: Lease liability - current portion $ 4,694,467 $ 3,534,073 Noncurrent liabilities: Lease liability, net of current portion 10,031,138 7,896,392 Total lease liability $ 14,725,605 $ 11,430,465 Lease Terms and Discount Rate The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of December 31, 2024: Weighted average remaining lease term (in years) - finance leases 3.45 Weighted average discount rate - finance leases 5.75 %
Schedule of future minimum lease payments under the operating leases	Future minimum lease payments under the operating leases as of December 31, 2024 are as follows: Operating 2025 $ 4,475,876 2026 3,832,409 2027 2,585,529 2028 1,763,468 2029 956,779 Thereafter 304,729 Total future minimum lease payments 13,918,790 Less effects of discounting (1,475,157) Present value of future minimum lease payments $ 12,443,633
Finance Lease, Liability, Fiscal Year Maturity	Future minimum lease payments under the finance leases as of December 31, 2024 are as follows: Finance Leases 2025 $ 5,417,251 2026 4,615,612 2027 3,396,644 2028 2,202,280 2029 660,590 Thereafter — Total future minimum lease payments 16,292,377 Less effects of discounting (1,566,772) Present value of future minimum lease payments $ 14,725,605

Other (Expense) Income (Tables)

Other (Expense) Income (Tables)	12 Months Ended
	Dec. 31, 2024
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income	The Company recognized $(939,724), $1,238,313 and $950,264 of other (expense) income for the years ended December 31, 2024 , 2023 and 2022, respectively, as set forth in the table below. Year Ended Other (expense) income 2024 2023 2022 Interest (expense) income, net $ (1,929,207) $ 1,684,399 $ 762,685 Gain on remeasurement of warrant liabilities — — 1,127,388 Change in fair value of contingent liability 9,392,133 1,437,525 — Finite-lived intangible asset impairment (8,306,591) — — Goodwill impairment — — (2,921,958) (Loss) gain on equity method investments (316,044) (343,336) 8,919 (Loss) gain on remeasurement of operating and finance leases (32,363) (866) 1,388,273 Gain on bargain purchase — — 1,593,612 Gain (loss) on disposal of fixed assets 23,682 (852,544) (21,173) ABC litigation — (1,000,000) — Other income (expense) 228,666 313,135 (987,482) Total other (expense) income $ (939,724) $ 1,238,313 $ 950,264

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of company’s effective tax rate	A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate consists of the following: Year Ended 2024 2023 2022 Statutory federal income tax benefit 21.00 % 21.00 % 21.00 % Permanent items 6.33 % 26.18 % 0.56 % State taxes, net of federal tax benefit 19.88 % 20.67 % 7.77 % Rate Change (3.57) % (0.04) % 0.17 % Effects of Rates Different from Statutory (0.35) % 0.04 % 0.01 % Other (9.73) % (29.54) % (3.64) % Change in valuation allowance 18.29 % (1.91) % (54.94) % Income tax provision (benefit) 51.85 % 36.40 % (29.07) %
Schedule of income tax expense (benefit)	The components of income tax expense (benefit) are as follows: For the Years Ended 2024 2023 2022 Current: Federal $ 6,182,372 $ 2,555,164 $ 1,493,772 State and local 4,739,545 5,782,335 502,872 $ 10,921,917 $ 8,337,499 $ 1,996,644 Deferred: Federal $ 3,250,410 $ 1,650,695 $ (7,683,475) State and local 216,095 (3,256,914) (2,649,791) Foreign — (375,300) 375,301 3,466,505 (1,981,519) (9,957,965) Total income tax expense (benefit) $ 14,388,422 $ 6,355,980 $ (7,961,321)
Schedule of deferred tax assets and liabilities	The temporary differences that give rise to deferred tax assets and liabilities are as follows: For the Years Ended 2024 2023 Deferred tax assets: Allowance for credit loss $ 1,519,406 $ 1,683,119 Accrued expenses 901,403 799,295 Lease liability 6,001,016 4,674,177 Stock compensation 5,982,385 5,039,590 Research and development expense 1,399,066 865,800 Net operating loss 8,990,407 4,568,113 Other (375,247) (471,694) Total deferred tax asset $ 24,418,436 $ 17,158,400 Valuation allowance (6,187,664) (1,207,673) Deferred income tax assets, net of allowance $ 18,230,772 $ 15,950,727 Deferred tax liabilities: Prepaid expenses $ (1,007,405) $ (780,767) Depreciation (1,252,332) (3,819,069) Right-of-use asset (5,903,840) (4,544,024) Amortization (1,645,161) 5,081,672 Total deferred tax liability $ (9,808,738) $ (4,062,188) Deferred tax assets, net of allowance $ 8,422,034 $ 11,888,539

Description of Organization a_2

Description of Organization and Business Operations (Details) - segment	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	3	3	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)							12 Months Ended
	Jul. 19, 2024	May 29, 2024	Apr. 02, 2024	Mar. 31, 2023	Aug. 09, 2022	Jul. 13, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jul. 01, 2024	Jan. 01, 2024	Dec. 09, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Total assets							$ 455,621,132	$ 490,451,957	$ 393,277,628
Total liabilities							140,442,002	185,281,001
Noncontrolling interests							(5,738,346)	4,376,089
Unrealized cumulative translation							(263,036)	743,699	773,707
Cash balances							4,020,221	3,699,793
Contingent consideration							4,973,152	19,792,982		$ 15,822,190
Change in fair value of contingent liability							(9,392,133)	(1,437,525)	0
Payment for contingent consideration liability							$ 3,608,553	$ 5,266,681	0
Common stock, par value (in Dollars per share)							$ 0.0001	$ 0.0001
Finite-lived intangible asset impairment							$ 8,306,591	$ 0	0
Accounts receivable, net of allowance							5,873,942	6,276,454			$ 6,276,454
Additional provision for credit losses							4,384,866
Accounts receivable, allowance for credit loss, writeoff							(4,787,379)
Impairment losses							$ 0	0	0
Lease term (in years)							10 years
Ryan Brothers Fort Atkinson LLC
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration					$ 4,000,000		$ 0	1,821,018
Contingent consideration period (in months)					24 months
Change in fair value of contingent liability							187,506	(338,956)	0
Payment for contingent consideration liability							2,008,524	1,840,026
Voting interest					100%
Exceptional Medical Transportation LLC
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration							265,538	279,301
Contingent consideration period (in months)						2 years
Change in fair value of contingent liability							(13,763)	(374,044)	0
Business combination, contingent consideration arrangements						$ 2,000,000
Payment for contingent consideration liability								426,655
Voting interest						100%
Location Medical Services LLC
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration							0	604,827				$ 2,475,540
Change in fair value of contingent liability							0	(2,000,312)	0
Payment for contingent consideration liability			$ 600,029
Contingent consideration, change from foreign exchange movement							(4,798)	129,599	$ 0
Voting interest												100%
CRMS
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration				$ 15,822,190			4,707,614	17,087,835
Contingent consideration period (in months)				36 months
Change in fair value of contingent liability							$ (9,565,876)	$ 1,265,645
Payment for contingent consideration liability		$ 1,000,000
Contingent consideration period to purchase remaining voting interest				49%
Business acquisition, equity interest issued	$ 1,814,345
Common stock, par value (in Dollars per share)	$ 0.0001
Business acquisition, equity interest issued (in shares)	578,350
Voting interest				51%
CRMS | True-Up Payment
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration				$ 2,088,243
CRMS | Earn Out Payment
Summary of Significant Accounting Policies (Details) [Line Items]
Contingent consideration				$ 13,733,947
Business Combination
Summary of Significant Accounting Policies (Details) [Line Items]
Voting interest							10%
Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk | Vendor One
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk							17%	14%	12%
Customer One | Revenue Benchmark | Customer Concentration Risk
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk							38%	40%	35%
Customer One | Accounts Receivable | Customer Concentration Risk
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk							39%	42%	45%
Customer Two | Revenue Benchmark | Customer Concentration Risk
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk							28%	21%
Customer Two | Accounts Receivable | Customer Concentration Risk
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk							37%	40%
Variable Interest Entity, Primary Beneficiary
Summary of Significant Accounting Policies (Details) [Line Items]
Net income (loss)							$ 231,952	$ 235,976	$ 373,456
Total assets							20,837,325	4,364,274
Total liabilities							21,516,860	4,811,857
Noncontrolling interests							$ 679,535	$ 447,583

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	Dec. 31, 2024
Buildings
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	39 years
Office equipment and furniture | Minimum
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	3 years
Office equipment and furniture | Maximum
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	7 years
Medical equipment
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	5 years
Vehicles | Minimum
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	5 years
Vehicles | Maximum
Summary of Significant Accounting Policies (Details) - Schedule of depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets [Line Items]
Estimated Useful Life	8 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of revenue is disaggregated (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 616,555,132	$ 624,288,642	$ 440,515,746
Mobile Health Services
Disaggregation of Revenue [Line Items]
Revenues	423,126,040	442,793,537	325,891,440
Transportation Services
Disaggregation of Revenue [Line Items]
Revenues	193,429,092	181,495,105	114,624,306
U.S.
Disaggregation of Revenue [Line Items]
Revenues	558,790,845	571,887,943	419,578,082
U.K.
Disaggregation of Revenue [Line Items]
Revenues	$ 57,764,287	$ 52,400,699	$ 20,937,664

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Net Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	$ 19,992,143	$ 6,858,455	$ 34,584,498
Weighted-average shares - basic (in shares)	102,395,141	103,511,299	101,228,369
Effect of dilutive options (in shares)	7,027,699	2,106,518	1,747,462
Weighted-average shares outstanding - Diluted (in shares)	109,422,840	105,617,817	102,975,831
Net income share - basic (in dollars per shares)	$ 0.20	$ 0.07	$ 0.34
Net income share - diluted (in dollars per shares)	$ 0.18	$ 0.06	$ 0.34
Anti-dilutive employee share-based awards excluded (in shares)	7,251,625	10,638,371	9,000,750

Property and Equipment, net (De

Property and Equipment, net (Details) - Schedule of property and equipment, net - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment	$ 32,608,070	$ 29,518,592
Less: Accumulated depreciation	(17,726,659)	(12,683,108)
Property and equipment, net	14,881,411	16,835,484
Transportation equipment
Property, Plant and Equipment [Line Items]
Property and equipment	17,300,595	17,438,072
Medical equipment
Property, Plant and Equipment [Line Items]
Property and equipment	9,210,203	7,104,161
Office equipment and furniture
Property, Plant and Equipment [Line Items]
Property and equipment	4,293,100	3,701,657
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	1,239,089	709,619
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment	527,283	527,283
Land
Property, Plant and Equipment [Line Items]
Property and equipment	$ 37,800	$ 37,800

Property and Equipment, net - N

Property and Equipment, net - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Disposals of assets	$ 758,859	$ 12,343,547	$ 50,353
Accumulated depreciation of assets disposed	509,378	10,743,915	26,180
Proceeds from disposal of property and equipment	274,427	747,088	3,000
Gain (loss) on disposal of assets	24,946	(852,544)	(21,173)
Depreciation expense	$ 5,606,818	$ 4,829,780	$ 4,114,346

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($)											12 Months Ended			15 Months Ended
	Jul. 19, 2024	Jul. 01, 2024	May 29, 2024	Apr. 02, 2024	May 10, 2023	Apr. 01, 2023	Mar. 31, 2023	Dec. 09, 2022	Aug. 09, 2022	Jul. 13, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jul. 02, 2024
Acquisition of Businesses (Details) [Line Items]
Deferred consideration		$ 0
Due to seller											$ 28,656	$ 7,823,009
Change in fair value of contingent liability											(9,392,133)	(1,437,525)	$ 0
Payment for contingent consideration liability											3,608,553	5,266,681	0
Contingent consideration		15,822,190									4,973,152	19,792,982
Consideration transferred														$ 34,670,190
Cash consideration														14,848,000
Stock consideration														$ 4,000,000
Exceptional Medical Transportation LLC
Acquisition of Businesses (Details) [Line Items]
Voting interest										100%
Total consideration										$ 13,708,333
Cash										7,708,333
Deferred consideration										6,000,000	0	3,000,000
Business combination, contingent consideration arrangements										$ 2,000,000
Performance condition period (in years)										2 years
Accounts receivable, due to seller, writeoff											1,315,691
Accounts receivable, due to seller, paid											109,619
Business combination, payments for deferred consideration											3,000,000	3,000,000
Due to seller											28,656	1,453,966
Change in fair value of contingent liability											(13,763)	(374,044)	0
Payment for contingent consideration liability												426,655
Contingent consideration											265,538	279,301
Business Combination, Contingent Consideration Period										2 years
Ryan Brothers Fort Atkinson LLC
Acquisition of Businesses (Details) [Line Items]
Voting interest									100%
Deferred consideration											0	3,369,043
Business combination, payments for deferred consideration											8,976
Change in fair value of contingent liability											187,506	(338,956)	0
Payment for contingent consideration liability											2,008,524	1,840,026
Contingent consideration									$ 4,000,000		0	1,821,018
Consideration transferred									11,422,252
Cash consideration									$ 7,422,252
Pre-acquisition accounts receivables written off											3,360,067
Business Combination, Contingent Consideration Period									24 months
Location Medical Services LLC
Acquisition of Businesses (Details) [Line Items]
Voting interest								100%
Deferred consideration								$ 11,279,201			0	0
Business combination, payments for deferred consideration												11,279,201
Change in fair value of contingent liability											0	(2,000,312)	0
Payment for contingent consideration liability				$ 600,029
Contingent consideration								2,475,540			0	604,827
Cash consideration								$ 302,450
Contingent consideration, change from foreign exchange movement											(4,798)	129,599	$ 0
CRMS
Acquisition of Businesses (Details) [Line Items]
Voting interest							51%
Deferred consideration							$ 0
Change in fair value of contingent liability											(9,565,876)	1,265,645
Payment for contingent consideration liability			$ 1,000,000
Contingent consideration							15,822,190				$ 4,707,614	17,087,835
Consideration transferred							25,822,190
Cash consideration							9,000,000
Closing consideration							10,000,000
Stock consideration							$ 1,000,000
Business Combination, Contingent Consideration Period							36 months
Contingent consideration period to purchase remaining voting interest							49%
Business combination, contingent consideration, liability to be paid in cash							$ 5,000,000
Business combination, contingent consideration, liability to be paid shares							10,822,190
Acquisition costs												229,937
Business acquisition, equity interest issued	$ 1,814,345
Business acquisition, equity interest issued (in shares)	578,350
CRMS | True-Up Payment
Acquisition of Businesses (Details) [Line Items]
Contingent consideration							2,088,243
CRMS | Earn Out Payment
Acquisition of Businesses (Details) [Line Items]
Contingent consideration							$ 13,733,947
FMC NA
Acquisition of Businesses (Details) [Line Items]
Deferred consideration						$ 0
Contingent consideration						0
Consideration transferred						7,000,000
Cash consideration						4,000,000
Stock consideration						$ 3,000,000
Acquisition costs												$ 35,560
Rapid Reliable Testing
Acquisition of Businesses (Details) [Line Items]
Cash consideration					$ 1,385,156
Ambulnz CO
Acquisition of Businesses (Details) [Line Items]
Deferred consideration		0
Contingent consideration		0
Consideration transferred		1,848,000
Cash consideration		1,848,000
Stock consideration		$ 0

Acquisitions - Schedule of prel

Acquisitions - Schedule of preliminary allocation of assets acquired and liabilities assumed (Details) - USD ($)				15 Months Ended
	Jul. 01, 2024	Apr. 01, 2023	Mar. 31, 2023	Jul. 02, 2024	Dec. 31, 2024	Dec. 31, 2023
Consideration:
Cash consideration				$ 14,848,000
Stock consideration				4,000,000
Due to seller	$ 0
Amounts held under an escrow account	0
Contingent liability	15,822,190				$ 4,973,152	$ 19,792,982
Total consideration				34,670,190
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	1,574,604
Accounts receivable	2,033,533
Other current assets	293,478
Property and equipment	0
Intangible assets	15,930,000
Total identifiable assets acquired	19,831,615
Accounts payable	28,978
Due to seller	2,448,460
Other current liabilities	174,177
Total liabilities assumed	2,651,615
Noncontrolling interests	4,755,487
Goodwill				$ 8,642,190
Additional paid-in-capital	4,092,513
Total purchase price	34,670,190
Ambulnz CO
Consideration:
Cash consideration	1,848,000
Stock consideration	0
Due to seller	0
Amounts held under an escrow account	0
Contingent liability	0
Total consideration	1,848,000
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	0
Accounts receivable	0
Other current assets	0
Property and equipment	0
Intangible assets	0
Total identifiable assets acquired	0
Accounts payable	0
Due to seller	0
Other current liabilities	0
Total liabilities assumed	0
Noncontrolling interests	2,188,450
Goodwill	0
Additional paid-in-capital	(340,450)
Total purchase price	$ 1,848,000
FMC NA
Consideration:
Cash consideration		$ 4,000,000
Stock consideration		3,000,000
Due to seller		0
Amounts held under an escrow account		0
Contingent liability		0
Total consideration		7,000,000
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash		0
Accounts receivable		0
Other current assets		0
Property and equipment		0
Intangible assets		0
Total identifiable assets acquired		0
Accounts payable		0
Due to seller		0
Other current liabilities		0
Total liabilities assumed		0
Noncontrolling interests		2,567,037
Goodwill		0
Additional paid-in-capital		4,432,963
Total purchase price		$ 7,000,000
CRMS
Consideration:
Cash consideration			$ 9,000,000
Stock consideration			1,000,000
Due to seller			0
Amounts held under an escrow account			0
Contingent liability			15,822,190		$ 4,707,614	$ 17,087,835
Total consideration			25,822,190
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash			1,574,604
Accounts receivable			2,033,533
Other current assets			293,478
Property and equipment			0
Intangible assets			15,930,000
Total identifiable assets acquired			19,831,615
Accounts payable			28,978
Due to seller			2,448,460
Other current liabilities			174,177
Total liabilities assumed			2,651,615
Noncontrolling interests			0
Goodwill			8,642,190
Additional paid-in-capital			0
Total purchase price			$ 25,822,190

Acquisitions (Details) - Schedu

Acquisitions (Details) - Schedule of pro forma combined financial information - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Revenue	$ 627,402,261	$ 539,522,587
Net income	$ 11,087,122	$ 46,960,359

Goodwill- Narrative (Details)

Goodwill- Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 2,921,958
Goodwill acquired during the period	0	8,642,190
Goodwill	$ 47,432,550	$ 47,539,929	$ 38,900,413

Goodwill - Schedule of changes

Goodwill - Schedule of changes in the carrying value of goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning balance	$ 47,539,929	$ 38,900,413
Goodwill acquired during the period	0	8,642,190
Currency translation adjustment and others	(107,379)	(2,674)
Ending balance	$ 47,432,550	$ 47,539,929

Intangibles - Schedule of Intan

Intangibles - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Impairment	$ (8,306,591)	$ 0	$ 0
Accumulated Amortization	(18,109,547)	$ (12,469,596)
Net Carrying Amount	$ 14,767,259
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]	Impairment	Impairment
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Gross Carrying Amount	$ 50,152,524	$ 30,180,863
Additions	1,992,427	19,971,661
Impairment	(8,306,591)	0
Accumulated Amortization	18,109,547	12,469,596
Net Carrying Amount	$ 25,728,813	$ 37,682,928
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]	Impairment	Impairment
Operating licenses
Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 9,399,004	$ 8,799,004
Additions	0	600,000
Impairment	0	0
Net Carrying Amount	9,399,004	9,399,004
Material contracts
Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	62,550	62,550
Additions	0	0
Impairment	0	0
Net Carrying Amount	$ 62,550	$ 62,550
Computer software
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Gross Carrying Amount	$ 247,828	$ 247,828
Additions	0	0
Impairment	0	0
Accumulated Amortization	(242,059)	(235,967)
Net Carrying Amount	5,769	11,861
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	242,059	235,967
Internally developed software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,078,087	8,284,058
Additions	2,051,826	1,794,029
Impairment	0	0
Accumulated Amortization	(11,227,960)	(8,821,563)
Net Carrying Amount	901,953	1,256,524
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ 11,227,960	$ 8,821,563
Internally developed software | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	4 years	4 years
Internally developed software | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 28,337,524	$ 12,397,954
Additions	(37,400)	15,939,570
Impairment	(8,306,591)	0
Accumulated Amortization	(6,504,390)	(3,334,925)
Net Carrying Amount	13,489,143	25,002,599
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ 6,504,390	$ 3,334,925
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	8 years	8 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	9 years	9 years
Trademark
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 427,531	$ 389,469
Additions	(21,999)	38,062
Impairment	0	0
Accumulated Amortization	(100,138)	(62,141)
Net Carrying Amount	305,394	365,390
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ 100,138	$ 62,141
Trademark | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	8 years	8 years
Trademark | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	15 years	15 years
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Gross Carrying Amount	$ 100,000	$ 0
Additions	0	100,000
Impairment	0	0
Accumulated Amortization	(35,000)	(15,000)
Net Carrying Amount	65,000	85,000
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ 35,000	$ 15,000
Trade credits
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	5 years	5 years
Gross Carrying Amount	$ 1,500,000	$ 0
Additions	0	1,500,000
Impairment	0	0
Accumulated Amortization	0	0
Net Carrying Amount	1,500,000	1,500,000
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ 0	$ 0

Intangibles - Narrative (Detail

Intangibles - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived intangible assets, foreign currency translation adjustment	$ (12,455)
Disposed of intangible assets	1,540	$ 0	$ 0
Accumulated amortization	276
Loss on disposition of intangible assets	1,264
Intangible assets, reclassification	30,361
Accumulated amortization, reclassifications	8,136
Finite-lived intangible asset impairment	8,306,591	0	0
Amortization expense	$ 5,660,818	$ 5,249,358	$ 3,214,814

Intangibles - Schedule of amort

Intangibles - Schedule of amortization expense for the next five years in aggregate (Details)	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 2,839,672
2026	2,167,093
2027	2,149,822
2028	2,113,652
2029	2,080,148
Thereafter	3,416,872
Total	$ 14,767,259

Investments - Schedule of Carry

Investments - Schedule of Carrying Amount of Investments (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity investment without readily determinable fair value	$ 5,000,000	$ 0
Equity method investment	547,979	553,573
Total investments	$ 5,547,979	$ 553,573

Investments - Narrative (Detail

Investments - Narrative (Details)					12 Months Ended
	Oct. 25, 2024 USD ($)	Dec. 21, 2021 member	Nov. 01, 2021 USD ($)	Oct. 26, 2021 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity securities					$ 5,000,000	$ 0	$ 0
Impairment losses					0	0	0
Equity securities without readily determinable fair value, amount upward price adjustment,					0
Equity securities without readily determinable fair value, amount					5,000,000	0
Payments to acquire equity method investments					$ 310,450	$ 298,932	$ 0
Firefly Health, Inc
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity securities	$ 5,000,000
RND Health Services Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage				50%	50%	50%
Payments to acquire equity method investments				$ 655,876	$ 310,450	$ 298,932
National Providers Association, LLC
Schedule of Equity Method Investments [Line Items]
Ownership percentage			20%
Payments to acquire equity method investments			$ 30,000
Number of members withdrawn from National Providers Association, LLC | member		3
Number of remaining members in National Providers Association, LLC | member		2

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Accrued Liabilities [Abstract]
Accrued workers' compensation and other insurance liabilities	$ 16,738,835	$ 12,881,902
Accrued general expenses	13,924,809	27,001,232
Accrued subcontractors	9,174,499	37,858,755
Accrued payroll	4,374,654	6,464,192
Accrued bonus	3,078,445	4,784,005
Other current liabilities	2,605,554	2,350,523
Total accrued liabilities	$ 49,896,796	$ 91,340,609

Line of Credit (Details)

Line of Credit (Details)								12 Months Ended
	Dec. 20, 2024 USD ($)	Mar. 18, 2024 USD ($)	Mar. 04, 2024 USD ($)	Feb. 27, 2024 USD ($)	Feb. 08, 2024 USD ($)	Oct. 20, 2023 USD ($)	Nov. 01, 2022 USD ($) bank	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Line of Credit (Details) [Line Items]
Number of banks with agreements | bank							2
Number of banks, administrative agent | bank							1
Maximum amount outstanding during period							$ 90,000,000
Line of credit facility, increase							$ 50,000,000
Letters of credit outstanding								$ 0
Revolving Credit Facility
Line of Credit (Details) [Line Items]
Debt instrument, term (in years)							5 years
Letter of Credit
Line of Credit (Details) [Line Items]
Debt instrument, term (in years)	1 year					1 year
Debt instrument, face amount	$ 133,303					$ 1,080,000
Debt instrument, renewal term (in years)	1 year					1 year
Line of Credit | Revolving Credit Facility
Line of Credit (Details) [Line Items]
Outstanding balance of the line of credit								30,000,000	$ 25,000,000
Proceeds from long-term lines of credit		$ 15,000,000	$ 15,000,000		$ 15,000,000
Repayments of long-term lines of credit				$ 40,000,000
Unused line of credit								60,000,000
Interest expense								$ 2,162,753	$ 359,330
Line of Credit | Secured Overnight Financing Rate
Line of Credit (Details) [Line Items]
Variable rate							1.25%
Line of Credit | Base Rate
Line of Credit (Details) [Line Items]
Variable rate							0.25%

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Notes Payable (Details) [Line Items]
Aggregate installment amount	$ 1,082
Repayments of notes payable	51,987	$ 25,926	$ 925,151
Notes payable	17,730	69,717
Notes Payable
Notes Payable (Details) [Line Items]
Interest expense, debt	3,407	$ (201,883)	$ 117,664
Note Payable Due August 2026
Notes Payable (Details) [Line Items]
Repayments of notes payable	$ 38,949
Minimum
Notes Payable (Details) [Line Items]
Interest range percentage	2.50%
Maximum
Notes Payable (Details) [Line Items]
Interest range percentage	4.80%

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of notes payable - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Notes Payable (Details) - Schedule of notes payable (Parentheticals) [Line Items]
Equipment and financing loans payable, between 2.5% and 4.8% interest and maturing on May 2026 and August 2026	$ 17,730	$ 69,717
Total notes payable	17,730	69,717
Less: current portion of notes payable	12,515	28,131
Total non-current portion of notes payable	$ 5,215	$ 41,586
Minimum
Notes Payable (Details) - Schedule of notes payable (Parentheticals) [Line Items]
Interest rate	2.50%
Maximum
Notes Payable (Details) - Schedule of notes payable (Parentheticals) [Line Items]
Interest rate	4.80%

Notes Payable (Details) - Sch_2

Notes Payable (Details) - Schedule of future minimum annual maturities of notes payable	Dec. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 12,515
2026	5,215
Total maturities	17,730
Current portion of notes payable	(12,515)
Long-term portion of notes payable	$ 5,215

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative Warrant Liabilities (Details) [Line Items]
Gain on remeasurement of warrant liabilities	$ 0	$ 0	$ 1,127,388	$ 5,200,000
Warrants exercise (in shares)			1,406,371
Redemption of warrant (in shares)			68,514
Warrant per share (in dollars per share)			$ 0.10
Warrants liabilities outstanding	$ 0	$ 0	$ 0
Public Warrants
Derivative Warrant Liabilities (Details) [Line Items]
Number of warrants outstanding (in shares)				3,833,333
Fair value				$ 8,100,000
Private Placement Warrants
Derivative Warrant Liabilities (Details) [Line Items]
Number of warrants outstanding (in shares)				2,533,333
Fair value				$ 5,400,000

Business Segment Information -

Business Segment Information - Narrative (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023 segment	Dec. 31, 2024 segment	Dec. 31, 2022 revenueStream segment
Segment Reporting [Abstract]
Number of operating segments | segment	3	3	2
Number of revenue streams | revenueStream			2

Business Segment Information _2

Business Segment Information - Schedule of Operating Results for the Business Segments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenues, net	$ 616,555,132	$ 624,288,642	$ 440,515,746
Significant Segment Expenses	445,213,216	475,069,862	326,085,501
Personnel costs	270,038,781	279,079,260	208,543,187
Subcontractor costs	149,887,849	174,497,607	93,749,904
Vehicle costs	25,286,586	21,492,995	23,792,410
Other segment items	142,653,190	134,163,800	92,598,617
Income (loss) from operations	28,688,726	15,054,980	21,831,628
Depreciation and amortization expense	15,884,898	16,431,892	10,565,578
Stock compensation	13,634,086	20,969,174	8,054,571
Finite-lived intangible asset impairment	8,306,591	0	0
Change in fair value of contingent liability	(9,392,133)	(1,437,525)	0
Total assets	455,621,132	490,451,957	393,277,628
Long-lived assets	115,338,771	123,642,795	101,241,774
Capital expenditures	14,318,974	51,015,538	94,217,852
Mobile Health Services
Segment Reporting Information [Line Items]
Revenues, net	423,126,040	442,793,537	325,891,440
Mobile Health Services | Operating Segments
Segment Reporting Information [Line Items]
Revenues, net	423,126,040	442,793,537	325,891,440
Significant Segment Expenses	248,887,401	283,980,203	189,978,467
Personnel costs	115,480,700	122,233,677	95,636,747
Subcontractor costs	125,495,305	155,134,128	83,158,899
Vehicle costs	7,911,396	6,612,398	11,182,821
Other segment items	80,212,789	78,450,514	43,202,810
Income (loss) from operations	94,025,850	80,362,820	92,710,163
Depreciation and amortization expense	4,770,367	4,226,657	1,685,114
Stock compensation	6,033,516	1,698,350	1,425,299
Finite-lived intangible asset impairment	8,306,591	0	0
Change in fair value of contingent liability	(9,392,133)	(1,437,525)	0
Total assets	208,739,901	280,646,925	116,821,500
Long-lived assets	36,515,356	32,841,680	33,181,594
Capital expenditures	2,815,218	30,163,882	39,569,802
Transportation Services
Segment Reporting Information [Line Items]
Revenues, net	193,429,092	181,495,105	114,624,306
Transportation Services | Operating Segments
Segment Reporting Information [Line Items]
Revenues, net	193,429,092	181,495,105	114,624,306
Significant Segment Expenses	157,386,875	146,950,131	102,697,543
Personnel costs	120,548,486	116,689,011	81,851,310
Subcontractor costs	19,463,199	15,380,523	8,236,644
Vehicle costs	17,375,190	14,880,597	12,609,589
Other segment items	38,087,398	31,003,597	26,472,934
Income (loss) from operations	(2,045,181)	3,541,377	(14,546,171)
Depreciation and amortization expense	8,305,049	9,393,895	6,050,265
Stock compensation	274,207	1,434,505	1,415,670
Finite-lived intangible asset impairment	0	0	0
Change in fair value of contingent liability	0	0	0
Total assets	134,169,086	132,178,214	118,627,613
Long-lived assets	68,846,225	78,848,587	65,580,291
Capital expenditures	9,324,171	20,254,373	52,105,196
Corporate | Operating Segments
Segment Reporting Information [Line Items]
Revenues, net	0	0	0
Significant Segment Expenses	38,938,940	44,139,528	33,409,491
Personnel costs	34,009,595	40,156,572	31,055,130
Subcontractor costs	4,929,345	3,982,956	2,354,361
Vehicle costs	0	0	0
Other segment items	24,353,003	24,709,689	22,922,873
Income (loss) from operations	(63,291,943)	(68,849,217)	(56,332,364)
Depreciation and amortization expense	2,809,482	2,811,340	2,830,199
Stock compensation	7,326,363	17,836,319	5,213,602
Finite-lived intangible asset impairment	0	0	0
Change in fair value of contingent liability	0	0	0
Total assets	112,712,145	77,626,818	157,828,515
Long-lived assets	9,977,190	11,952,528	2,479,889
Capital expenditures	$ 2,179,585	$ 597,283	$ 2,542,854

Business Segment Information _3

Business Segment Information - Long-Lived Assets by Geographic Areas (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 115,338,771	$ 123,642,795	$ 101,241,774
U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	96,380,597	103,779,506	83,145,362
U.K.
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 18,958,174	$ 19,863,289	$ 18,096,412

Equity (Details)

Equity (Details) - USD ($)			3 Months Ended		12 Months Ended
	Jul. 19, 2024	Jan. 30, 2024	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Aug. 05, 2024	May 24, 2022
Share Repurchase Program [Line Items]
Stock repurchased and cancelled (in shares)					3,647,342
Stock repurchased and cancelled					$ 13,756,271
Common stock repurchased (in shares)						0
CRMS
Share Repurchase Program [Line Items]
Business acquisition, equity interest issued	$ 1,814,345
Business acquisition, equity interest issued (in shares)	578,350
2022 Program
Share Repurchase Program [Line Items]
Common stock repurchased amount								$ 40,000,000
Shares repurchased (in shares)			536,839	536,839
Shares repurchased			$ 3,731,712	$ 3,731,712
Prior Repurchase Program
Share Repurchase Program [Line Items]
Common stock repurchased amount		$ 36,000,000
Stock repurchase program, period in force		6 months
New Repurchase Program
Share Repurchase Program [Line Items]
Common stock repurchased amount							$ 26,000,000

Stock Based Compensation - Narr

Stock Based Compensation - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reserved shares (in shares)				16,607,894
Contractual term	10 years
Employee stock options on a converted basis had vested (in shares)	4,900,000
Dividend yield	0%	0%
Weighted average fair value per share (in dollars per share)	$ 3.59	$ 7.93
Stock based compensation expense	$ 13,634,086	$ 20,969,174	$ 8,054,571
Total unrecognized compensation related to unvested stock option awards granted	$ 11,246,649	29,058,756	41,666,564
Weighted average period (in years)	1 year 5 months 4 days
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation expense	$ 6,652,789	11,795,320	6,232,992
Options | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Options | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	5 years
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation expense	$ 5,783,838	9,101,027	1,821,579
Grant-date fair value	11,854,256
Stock based compensation expense included in accrued liabilities	0	493,043
Unrecognized compensation cost	$ 17,458,680	12,602,662	$ 2,177,713
Weighted average period (in years)	2 years
Restricted Stock Units (RSUs) | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units (RSUs) | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation expense	$ 1,197,459	72,827
Grant-date fair value	9,529,994
Unrecognized compensation cost	$ 8,332,535	$ 5,527,166
Weighted average period (in years)	3 years
Performance Shares | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Performance Shares | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years

Stock Based Compensation (Detai

Stock Based Compensation (Details) - Schedule of Fair Value of Stock Option Assumptions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate, minimum	4.20%	4.10%
Risk-free interest rate, maximum	4.50%	4.90%
Expected term (in years)	5 years 6 months 21 days	6 years 3 months
Volatility, minimum	61%	52%
Volatility, maximum	71%	62%
Dividend yield	0%	0%

Stock Based Compensation (Det_2

Stock Based Compensation (Details) - Schedule of company’s stock option activity - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Options Shares
Beginning Balance (in shares)	11,942,264	11,571,308
Granted/Vested during the year (in shares)	506,822	1,566,010
Exercised during the year (in shares)	(16,559)	(514,065)
Cancelled during the year (in shares)	(4,265,031)	(680,989)
Ending Balance (in shares)	8,167,496	11,942,264	11,571,308
Options Shares, Options vested and exercisable (in shares)	4,944,286
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 7.36	$ 7.11
Granted/Vested during the year (in dollars per share)	3.59	7.93
Exercised during the year (in dollars per share)	1.59	3.55
Cancelled during the year (in dollars per share)	7.69	7.52
Ending balance (in dollars per share)	6.98	$ 7.36	$ 7.11
Weighted Average Exercise Price, Options vested and exercisable (in dollars per share)	$ 6.95
Weighted Average Remaining Contractual Life in Years
Weighted average remaining contractual life in years	7 years 3 months 25 days	8 years 1 month 28 days	9 years 18 days
Weighted Average Remaining Contractual Life in Years, Options vested and exercisable	6 years 9 months 25 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value	$ 2,521,202	$ 3,961,556	$ 39,389,063
Aggregate Intrinsic Value, Options vested and exercisable	$ 2,233,701

Stock Based Compensation (Det_3

Stock Based Compensation (Details) - Schedule of activity under RSUs - Restricted Stock Units (RSUs)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
RSUs
Beginning balance (in shares) | shares	2,424,095
Granted (in shares) | shares	3,009,868
Vested (in shares) | shares	(1,205,460)
Forfeited (in shares) | shares	(159,516)
Ending balance (in shares) | shares	4,068,987
Vested and unissued (in shares) | shares	10,990
Nonvested (in shares) | shares	4,057,997
Weighted- Average Grant Date Fair Value Per RSU
Beginning balance (in dollars per share) | $ / shares	$ 5.61
Granted (in dollars per share) | $ / shares	3.94
Vested (in dollars per share) | $ / shares	4.82
Forfeited (in dollars per share) | $ / shares	4.92
Ending balance (in dollars per share) | $ / shares	4.63
Vested and unissued (in dollars per share) | $ / shares	3.42
Non-vested (in dollars per share) | $ / shares	$ 4.64

Stock Based Compensation (Det_4

Stock Based Compensation (Details) - Schedule of activity under PSUs - Performance Shares	12 Months Ended
	Dec. 31, 2024 $ / shares shares
PSUs
Beginning Balance (in shares) | shares	1,085,270
Granted (in shares) | shares	1,205,251
Vested (in shares) | shares	0
Performance adjustment (in shares) | shares	(217,054)
Vested and unissued (in shares) | shares	0
Ending Balance (in shares) | shares	2,073,467
Weighted-Average Grant Date Fair Value Per PSU
Beginning Balance (in dollars per share) | $ / shares	$ 5.16
Granted (in dollars per share) | $ / shares	4.19
Vested (in dollars per share) | $ / shares	0
Performance adjustment (in dollars per share) | $ / shares	5.16
Vested and unissued (in dollars per share) | $ / shares	0
Ending Balance (in dollars per share) | $ / shares	$ 4.60

Leases- Narrative (Details)

Leases- Narrative (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jan. 01, 2019	Jun. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Estimated borrowing rate	6%
(Loss) gain on remeasurement of operating leases			$ (13,469)	$ 4,566	$ 0
Present value of future minimum lease payments			14,725,605	11,430,465	8,646,803
Accumulated amortization			15,337,299	12,003,919	9,039,663
Accumulated depreciation			9,128,202	11,679,823	$ 7,906,966
(Loss) gain on remeasurement of finance leases		$ 1,400,000	$ (18,894)	$ (5,432)

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease expense	$ 3,851,686	$ 3,418,134	$ 2,294,636
Finance lease expense:
Amortization of finance lease right-of-use assets	4,617,262	6,352,754	3,236,418
Interest on lease liabilities	769,041	600,239	559,596
Finance lease expense	5,386,303	6,952,993	3,796,014
Short-term lease expense	2,580,933	1,678,487	1,201,622
Total lease cost	11,818,922	12,049,614	7,292,272
Operating lease payment	3,711,545	3,287,125	2,294,636
Finance lease payment	4,334,463	4,270,553	2,985,568
Total lease payments	$ 8,046,008	$ 7,557,678	$ 5,280,204

Leases - Schedule of Lease Asse

Leases - Schedule of Lease Assets and Liabilities in the Condensed Consolidated Balance Sheets (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets
Lease right-of-use assets	$ 11,958,698	$ 9,580,535
Total lease assets	11,958,698	9,580,535
Liabilities
Lease liability - current portion	3,844,561	2,773,020
Lease liability, net of current portion	8,599,072	7,223,941
Total lease liability	12,443,633	9,996,961
Assets
Lease right-of-use assets	15,337,299	12,003,919
Total lease assets	15,337,299	12,003,919
Liabilities
Lease liability - current portion	4,694,467	3,534,073
Lease liability, net of current portion	10,031,138	7,896,392
Total lease liability	$ 14,725,605	$ 11,430,465	$ 8,646,803

Leases - Schedule of Lease Term

Leases - Schedule of Lease Terms and Discount Rate (Details)	Dec. 31, 2024
Leases [Abstract]
Weighted average remaining lease term (in years) - operating leases	3 years 7 months 24 days
Weighted average discount rate - operating leases	5.86%
Weighted average remaining lease term (in years) - finance leases	3 years 5 months 12 days
Weighted average discount rate - finance leases	5.75%

Leases - Schedule of future min

Leases - Schedule of future minimum lease payments under the operating leases (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Leases
2025	$ 4,475,876
2026	3,832,409
2027	2,585,529
2028	1,763,468
2029	956,779
Thereafter	304,729
Total future minimum lease payments	13,918,790
Less effects of discounting	(1,475,157)
Present value of future minimum lease payments	12,443,633	$ 9,996,961
Finance Leases
2025	5,417,251
2026	4,615,612
2027	3,396,644
2028	2,202,280
2029	660,590
Thereafter	0
Total future minimum lease payments	16,292,377
Less effects of discounting	(1,566,772)
Present value of future minimum lease payments	$ 14,725,605	$ 11,430,465	$ 8,646,803

Other (Expense) Income - Schedu

Other (Expense) Income - Schedule of Other Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Income and Expenses [Abstract]
Interest (expense) income, net	$ (1,929,207)	$ 1,684,399	$ 762,685
Gain on remeasurement of warrant liabilities	0	0	1,127,388	$ 5,200,000
Change in fair value of contingent liability	9,392,133	1,437,525	0
Finite-lived intangible asset impairment	(8,306,591)	0	0
Goodwill impairment	0	0	(2,921,958)
(Loss) gain on equity method investments	(316,044)	(343,336)	8,919
(Loss) gain on remeasurement of operating and finance leases	(32,363)	(866)	1,388,273
Gain on bargain purchase	0	0	1,593,612
Gain (loss) on disposal of fixed assets	23,682	(852,544)	(21,173)
ABC litigation	0	(1,000,000)	0
Other Noncash Income (Expense)	228,666	313,135	(987,482)
Total other (expense) income	$ (939,724)	$ 1,238,313	$ 950,264

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)			12 Months Ended
	Sep. 26, 2024	Mar. 07, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Accounts payable			$ 28,356,430	$ 19,827,258
Accrued liabilities			49,896,796	91,340,609
Restricted Stock Units (RSUs)
Related Party Transaction [Line Items]
Grant-date fair value			11,854,256
Related Party
Related Party Transaction [Line Items]
Commission payments			1,207,843	916,370	$ 960,081
Related Party | Subcontractor Payments
Related Party Transaction [Line Items]
Accounts payable			17,149	0
Accrued liabilities			13,097	0
Related party transaction, amounts of transaction			155,749	0	547,500
Related Party | Transition Services Agreement Payments
Related Party Transaction [Line Items]
Accounts payable			0	45,000
Related Party | Legal Service Payments
Related Party Transaction [Line Items]
Accounts payable			55,545	0
Accrued liabilities			0	0
Former Chief Executive Officer | Related Party
Related Party Transaction [Line Items]
Monthly consulting fee			45,000
Former Chief Executive Officer | Related Party | Transition Services Agreement Payments
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction			180,000	90,000	0
Director and Chair of the Board | Consulting Agreement Consideration
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction		$ 35,000
Director and Chair of the Board | Consulting Agreement Consideration | Restricted Stock Units (RSUs)
Related Party Transaction [Line Items]
Grant-date fair value			105,000
Director and Chair of the Board | Related Party | Consulting Agreement Consideration
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities, current			0	0
Former Board Of Directors Chairman | Related Party
Related Party Transaction [Line Items]
Monthly consulting fee	$ 2,500
Hourly service fee	$ 400
Former Board Of Directors Chairman | Related Party | Consulting Agreement Consideration
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction			5,000	0	$ 0
Accounts payable and accrued liabilities, current			$ 2,500	$ 0

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of company’s effective tax rate	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory federal income tax benefit	21%	21%	21%
Permanent items	6.33%	26.18%	0.56%
State taxes, net of federal tax benefit	19.88%	20.67%	7.77%
Rate Change	(3.57%)	(0.04%)	0.17%
Effects of Rates Different from Statutory	(0.35%)	0.04%	0.01%
Other	(9.73%)	(29.54%)	(3.64%)
Change in valuation allowance	18.29%	(1.91%)	(54.94%)
Income tax provision (benefit)	51.85%	36.40%	(29.07%)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of income tax expense (benefit) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 6,182,372	$ 2,555,164	$ 1,493,772
State and local	4,739,545	5,782,335	502,872
Total	10,921,917	8,337,499	1,996,644
Deferred:
Federal	3,250,410	1,650,695	(7,683,475)
State and local	216,095	(3,256,914)	(2,649,791)
Foreign	0	(375,300)	375,301
Total	3,466,505	(1,981,519)	(9,957,965)
Total income tax expense (benefit)	$ 14,388,422	$ 6,355,980	$ (7,961,321)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Allowance for credit loss	$ 1,519,406	$ 1,683,119
Accrued expenses	901,403	799,295
Lease liability	6,001,016	4,674,177
Stock compensation	5,982,385	5,039,590
Research and development expense	1,399,066	865,800
Net operating loss	8,990,407	4,568,113
Other	(375,247)	(471,694)
Total deferred tax asset	24,418,436	17,158,400
Valuation allowance	(6,187,664)	(1,207,673)
Deferred income tax assets, net of allowance	18,230,772	15,950,727
Deferred tax liabilities:
Prepaid expenses	(1,007,405)	(780,767)
Depreciation	(1,252,332)	(3,819,069)
Right-of-use asset	(5,903,840)	(4,544,024)
Amortization	(1,645,161)	5,081,672
Total deferred tax liability	(9,808,738)	(4,062,188)
Deferred tax assets, net of allowance	$ 8,422,034	$ 11,888,539

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal net operating loss carryforward	$ 0	$ 0	$ 35,289,184
Foreign net operating loss carryforwards	24,273,354	10,737,510	1,520,345
State net operating loss carryforwards	36,878,259	36,422,543	2,592,560
Operating loss carryforwards, not subject to expiration	35,298,184
Valuation allowance for deferred tax assets	6,187,664	1,207,673
Increase (decrease) in valuation allowance	4,979,991	(312,672)
Unrecognized tax benefits, income tax penalties and interest expense	$ 0	$ 0	$ 0

401(k) Plan (Details)

401(k) Plan (Details)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Eligibility service period	2 months

Legal Proceedings (Details)

Legal Proceedings (Details) - claim	Jul. 15, 2024	May 30, 2024	Mar. 30, 2023
California Labor Actions
Loss Contingencies [Line Items]
Loss contingency, claims filed number			2
Stockholder Actions
Loss Contingencies [Line Items]
Loss contingency, claims filed number	2	2

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		15 Months Ended
	Feb. 10, 2025	Jul. 02, 2024	Jul. 01, 2024
Subsequent Event [Line Items]
Consideration transferred		$ 34,670,190
Cash consideration		$ 14,848,000
Deferred consideration			$ 0
Subsequent Event | Professional Technicians, Inc
Subsequent Event [Line Items]
Outstanding shares of common stock percentage	100%
Consideration transferred	$ 4,000,000
Cash consideration	3,800,000
Deferred consideration	$ 1,500,000